MOLECULAR PHARMACOLOGY 24:533-536

AUTHOR INDEX FOR VOLUME 24

A Brown, Susan L, and Brown, Joan Heller. Muscarmnic Stimulation Abell, Creed W. See Denney, Fritz, Patel, and Widen, 60 of Phosphatidylinositol Metabolism in Atria, 351 Ahotupa, Markku, and M#{228}ntyla, Eero. Adipose Tissue Content as Burgen, A. S. V. See Barrett, Roberts, and Clore, 443 a Modifier of the Tissue Distribution, Biological Effects, and Bylund, David B. See Forte and Zahler, 42 Excretion ofa Hexachiorobiphenyl in C57BL/6J and DBA/JBOMf Mice, 464 C Aktories, Klaus, Schultz, G#{252}nter, and Jakobs, Karl H. Somato- Camus, J. C. See Waelbroeck, Taton, Delhaye, Chatelain, Pochet, statin-Induced Stimulation of a High-Affinity GTPase in Mem- Leclerc, De Smet, Robberecht, and Christophe, 174 branes of 549 Lymphoma cyc and H21a Variants, 183 Cantoni, Orazio Alberta, P#{235}teris. See Nordstrom, Westlind, Und#{233}n,and Bartfai, 1 and Costa, Max. Correlations of DNA Strand Breaks and Their Alexander, R. Wayne. See Wright, Eckstein, and Gimbrone, 213 Repair with Cell Survival following Acute Exposure to Mercury(II) Alley, Michael C. See Brimijoin and Mintz, 513 and X-Rays, 84 Ames, Matthew M. See Woodson, Selassie, Hansch, and Weinshil- See Evans, Patierno, Wang, and Costa, 77 boum, 471 Catto, Brian A. See Tracy and Webster, 291 Anderson, D.C. Chatelain, P. King, Steven C., and Parsons, Stanley M. Inhibition of [3H] See Robberecht, Delhaye, Taton, De Neef, Waelbroeck, De Smet, Acetyicholine Active Transport by Tetraphenylborate and Other Leclerc, and Christophe, 169 Anions, 55 See Waelbroeck, Taton, Delhaye, Camus, Pochet, Leclerc, De Smet, King, Steven C., and Parsons, Stanley M. Pharmacological Char- Robberecht, and Christophe, 174 acterization of the Acetyicholine Transport System in Purified Chow, Thomas, and Zukin, Suzanne. Solubiization and Preliminary Torpedo Electric Organ Synaptic Vesicles, 48 Characterization of Mu and Kappa Opiate Receptor Subtypes Anderson, Leojean. See Schellenberg and Swanson, 251 from Rat Brain, 203 Christophe, J B See Robberecht, Delhaye, Taton, De Neef, Waelbroeck, De Smet, Barrett, A. N., Roberts, G. C. K., Burgen, A. S. V., and Clore, G. Leclerc, and Chatelain, 169 M. Ab Initio Molecular Orbital Calculations of Electron Distribu- See Waelbroeck, Taton, Delhaye, Chatelain, Camus, Pochet, Le- tion in Tetramethylammonium Ion, 443 clerc, De Smet, and Robberecht, 174 Bartfai, Tamas. See Nordstrom, Alberts, Westlind, and Und#{233}n, 1 Cirtain, Margaret C. See Beck and Lefko, 485 Battaglia, George, Shannon, Michael, and Pithier, Milt. Initial Clore, G. M. See Barrett, Roberts, and Burgen, 443 Detection of [3H}-Labeled Alpha,-Receptors in the Por- Colombo, Ambrogio. See Gambetta, Lanzi, and Zunino, 336 cine Pituitary Neurointermediate Lobe, 409 Conney, Allan H. See Miller, Huang, and Jeffrey, 137 Baudry, Michel Costa, Max Kramer, Kathryn, Fagni, Laurent, Recasens, Max, and Lynch, See Cantoni, 84 Gary. Classification and Properties of Acidic Amino Acid Recep- See Evans, Patierno, Wang, and Cantoni, 77 tors in Hippocampus. II. Biochemical Studies Using a Sodium Costa, Erminio Efflux Assay, 222 See Onali, Eva, Olianas, and Schwartz, 189 Kramer, Kathryn, and Lynch, Gary. Classification and Properties See Onali, Olianas, and Schwartz, 380 of Acidic Amino Acid Receptors in Hippocampus. III. Supersen- Croft, Jane E. See Robertson, Serabjit-Singh, and Philpot, 156 sitivity during the Postnatal Period and following Denervation, Cybuiska, B., Ziminski, T., Borowski, E., and Gary-Bobo, C. M. 229 The Influence of Electric Charge of Aromatic Heptaene Macrolide Beck, William T., Cirtain, Margaret C., and Leiko, Janet L Antibiotics on Their Activity on Biological and Lipidic Model Energy-Dependent Reduced Drug Binding as a Mechanism of Membranes, 270 Vinca Alkaloid Resistance in Human Leukemic Lymphoblasts, 485 Beerman, Terry. See Rauscher and Mueller, 97 D Belt, Judith A. Heterogeneity ofNucleoside Transport in Mammalian Cells: Two Types of Transport Activity in L1210 and Other Cul- Dethaye, M. tured Neoplastic Cells, 479 See Robberecht, Taton, De Neef, Waelbroeck, De Smet, Leclerc, Birkett, Donald J. See Wanwimoiruk and Brooks, 458 Chatelain, and Christophe, 169 Blount, John F., Fryer, R. Ian, Gilman, Norman W., and Todaro, See Waelbroeck, Taton, Chatelain, Camus, Pochet, Leclerc, De Louis J. Quinazolines and 1,4-benzodiazepines. 92. Conformational Smet, Robberecht, and Christophe, 174 Recognition of the Receptor by 1,4-Benzodiazepines, 425 De Neef, P. See Robberecht, Delhaye, Taton, Waelbroeck, De Smet, Bockaert, Joel. See Sladeczek and Mauger, 392 Leclerc, Chatelain, and Christophe, 169 Borowski, E. See Cybulska, Ziminski, and Gary-Bobo, 270 Denney, Richard M., Fritz, Richard R., Pate!, Nutan T., Widen, Bouchard, Jacques, and Momparler, Richard L Incorporation of Steven G., and Abel, Creed W. Use of a Monoclonal Antibody 5-Aza-2’-Deoxycytidine-5’-triphosphate into DNA: Interactions for Comparative Studies of Monoamine Oxidase B in Mitochon- with Mammalian DNA Polymerase a and DNA Methylase, 109 dna! Extracts of Human Brain and Peripheral Tissues, 60 Brimijoin, Stephen, Mintz, Keith P., and Alley, Michael C. Pro- De Smet, J. M. duction and Characterization of Separate Monoclonal Antibodies See Robberecht, Delhaye, Taton, De Neef, Waelbroeck, Leclerc, to Human Acetyicholinesterase and Butyrylcholinesterase, 513 Chatelain, and Christophe, 169 Brooks, Peter M. See Wanwimofruk and Birkett, 458 See Waelbroeck, Taton, Delhaye, Chatelain, Camus, Pochet, Le- Brown, Joan Heller clerc, Robberecht, and Chri.stophe, 174 See Dunlap, 15 Drewes, Lester R. See Zeleznikar and Quist, 163 See Heller, 351 Dub#{233}, Christopher E. See Murray, Wilkinson, and Marcus, 129

0026-895X/83/060533-04$02.00/0 Copyright © 1983 by The American Society for Pharmacology and Experimental Therapeutics. 533 All rights of reproduction in any form reserved. 534 AUTHOR INDEX

Duch, David S., Lee, Ching-Lun Lee, Edeistein, Mark P., and H

Nichol, Charles A. Biosynthesis of Tetrahydrobiopterin in the Haga, Tatsuya. See Nukada and Ichiyama, 366, 374 Presence of Dihydrofolate Reductase Inhibitors, 103 Hansch, Corwin. See Woodson, Ames, Selassie, and Weinshilboum, Dunlap, Janet, and Brown, Joan Heller. Heterogeneity of Binding 471 Sites on Cardiac Muscarinic Receptors Induced by the Neuromus- Hartley-Asp, Beryl. See Tew, Erickson, White, Wang, and Schein, cular Blocking Agents Gallamine and Pancuronium, 15 324 Hartman, Kathleen D. E See Glazer, 509 Eckstein, Laurie S. See Wright, Alexander, and Gimbrone, 213 See Glazer and Knode, 309 Edelstein, Mark P. See Duch, Lee, and Nichol, 103 Henis, Yoav I., and Sokolovsky, Mordechai. Muscarinic Antago- Erickson, Leonard C. See Tew, White, Wang, Schein, and Hartley- nists Induce Different Receptor Conformations in Rat Adenohy- Asp, 324 pophysis, 357 Eva, Carola. See Onali, Olianas, Schwartz, and Costa, 189 Herbette, L, Katz, A. M., and Sturtevant, J. M. Comparisons of Evans, R. Mark, Patierno, Steven R., Wang, De-Shin, Cantoni, the Interaction of Propranolol and Timolol with Model and Bio- Orazio, and Costa, Max. Growth Inhibition and Metallothionen logical Membrane Systems, 259 Induction in Cadmium-Resistant Cells by Essential and Non-Es- Hoffman, B. B. See Rosenkranz, Jacobson, Verlander, Kievans, sential Metals, 77 O’Donnell, Goodman, and Melmon, 429 Eyer, Peter, Lierheimer, Elisabeth, and Strosar, Mira. Site and Hom, D. S. See Law and Loh, 413 Mechanism of Covalent Binding of 4-Dimethylaminophenol to Huang, Mou-Tuan. See Miller, Jeffrey, and Conney, 137 Human Hemoglobin, and Its Implications to the Functional Prop- erties, 282 I Ichiyama, Arata. See Nukada and Haga, 366, 374 F Ishii, Kenji. See Kamataki, Maeda, Yamazoe, Matsuda, and Kato, Fagni, Laurent. See Baudry, Kramer, Recasens, and Lynch, 222 146 Fairhurst, Alan S. See Thayer, 6 J Fischer, Paul H., Murphy, David G., and Kawahara, Rodney. Preferential Inhibition of 5-Trifluoromethyl-2’-Deoxyuridine Jacobs, Robert S. Phosphorylation by 5’-Amino-5’-Deoxythymidine in Uninfected See O’Brien and Wilson, 493 versus Herpes Simplex Virus-Infected Cells, 90 See White, 500 Flaim, Kathryn E., Jefferson, Leonard S., McGwire, Joan B., and Jacobson, K. A. See Rosenkranz, Hoffman, Verlander, Kievans, Rannels, D. Eugene. Effect of Halothane on Synthesis and O’Donnell, Goodman, and Melmon, 429 Secretion of Liver Proteins, 277 Jakobs, Karl H. See Aktories and Schultz, 183 Florio, Vincent A., and Ross, Elliott M. Regulation of the Catalytic Jefferson, Leonard S. See Flaim, McGwire, and Rannels, 277 Component of Adenylate Cyclase: Potentiative Interaction of Jeffrey, Alan M. See Miller, Huang, and Conney, 137 Stimulatory Uganda and 2’,5’-Dideoxyadenosine, 195 Jerina, Donald M. See Vyas, van Bladeren, Thakker, Yagi, Sayer, Forte, Leonard R., Bylund, David B., and Zahier, Warren L andLevin, 115 Forskolin Does Not Activate Sperm Adenylate Cyclase, 42 Jung, Chan Y. See Lilly, Fraser, Seeman, and Venter, 10 Fraser, Claire M. See Lilly, Jung, Seeman, and Venter, 10 K Fi-it; Richard R. See Denney, Patel, Widen, and Abell, 60 Froimowitz, Mark, and Matthysse, Steven. Conformational Prop- Kador, Peter F., and Sharpless, Norman E. Pharmacophor Re- erties of Butaclamol and Isobutaclamol: Regularities in the Struc- quirements of the Aldose Reductase Inhibitor Site, 521 tures of Semirigid Neuroleptics, 243 Kamataki, Tetsuya, Maeda, Kaori, Yamazoe, Yasusbi, Matsuda, Fryer, R. Ian. See Blount, Gilman, and Todaro, 425 Naomi, Ishii, Kenji, and Kato, Ryuichi. A High-Spin Form of Fyfe, James A., McKee, Susan A., and Keller, Paul M. Thymidine- Cytochrome P-450 Highly Purified from Polychlorinated Biphenyl- Thymidylate Kinases from Strains of Herpes Simplex Virus with Treated Rats: Catalytic Characterization and Immunochemical Modified Drug Sensitivities to Acyclovir and (E)-5-(2-Bromovi- Quantitation in Liver Microsomes, 146 nyl)-2’-deoxyuridine, 316 Kate, Ryuichi. See Kamataki, Maeda, Yamazoe, Matsuda, and Ishii, 146 G Katz, A. M. See Herbette and Sturtevant, 259 Gambetta, Romolo A., Colombo, Ambrogio, Lanzi, Cinzia, and Kawahara, Rodney. See Fischer and Murphy, 90 Zunino, Franco. Purification and Partial Characterization of a Kellar, Kenneth J. See Schwartz, 387 Daunorubicin-Binding Protein from Rat Liver, 336 Keller, Paul M. See Fyfe and McKee, 316 Gans, Joseph H. See Mulcahy, 329 King, Steven C. See Anderson and Parsons, 48,55 Gary-Bobo, C. M. See Cybul.ska, Ziminski, and Borowski, 270 Kievans, L. See Rosenkranz, Hoffman, Jacobson, Verlander, Gilman, Norman W. See Blount, Fryer, and Todaro, 425 O’Donnell, Goodman, and Melmon, 429 Gimbrone, Michael A, Jr. See Wright, Alexander, and Eckstein, Knode, Marian C. See Glazer and Hartman, 309 213 Kouakou, Yao. See Meunier, Puget, and Moisand, 23 Glazer, Robert I. Kramer, Kathryn. See Baudry and Lynch, 229 and Hartman, Kathleen D. In Vitro Translational Activity of See Baudry, Fagni, Recasens, and Lynch, 222 Messenger RNA following Treatment of Human Colon Carcinoma Kuhar, Michael J. See Zarbin, Palacios, and Wamsley, 341 Cells with Sangivamycin, 509 L Hartnian, Kathleen D., and Knode, Marian C. 9-Deazaadenosine: Cytocidal Activity and Effects on Nucleic Acids and Protein Syn- Lanzi, Cinzia. See Gambetta, Colombo, and Zunino, 336 thesis in Human Colon Carcinoma Cells in Culture, 309 Law, P. Y., Horn, D. S., and Loh, H. H. Opiate Receptor Down- Goldblum, Amiram. Structure-Activity Relationships of Cholinester- Regulation and Desensitization in Neuroblastoma x Glioma ase Inhibitors. I. Quantum Mechanical Study of Affinities of NH1O8-15 Hybrid Cells Are Two Separate Cellular Adaptation Phenyl N-Methyl Carbamates, 436 Processes, 413 Goodman, M. See Rosenkranz, Hoffman, Jacobson, Verlander, Leclerc, J. L. Kievans, O’Donnell, and Melmon, 429 See Robberecht, Delhaye, Taton, De Neef, Waelbroeck, De Smet, AUTHOR INDEX 535

Chatelain, and Christophe, 169 Porcine Caudate Nucleus. I. Enhancement by Nickel and Other See Waelbroeck, Taton, Delhaye, Chatelain, Camus, Pochet, De Cations of[3H]cis-Methyldioxolane Binding to Guanyl Nucleotide- Smet, Robberecht, and Christophe, 174 Sensitive Sites, 366 Lee, Ching-Lun Lee. See Duch, Edeistein, and Nichol, 103 Haga, Tatsuya, and Ichiyama, Arata. Muscarinic Receptors in Iefko, Janet L. See Beck and Cirtain, 485 Porcine Caudate Nucleus. II. Different Effects of N-Ethylmaleim- Levin, Wayne. See Vyas, van Bladeren, Thakker, Yagi, Sayer, and ide on [3H]cis-Methyldioxolane Binding to Heat-Labile (Guanyl Jerina, 115 Nucleotide-Sensitive) Sites and Heat-Stable (Guanyl Nucleotide- Lierheimer, Elisabeth. See Eyer and Strosar, 282 Insensitive) Sites, 374 Lffly, Leslie, Fraser, Claire M., Jung, Chan Y., Seeman, Philip, and Venter, J. Craig. Molecular Size of the Canine and Human 0 Brain D2 Dopamine Receptor as Determined by Radiation Inac- O’Brien, E. Timothy, Jacobs, Robert S., and Wilson, Leslie. tivation, 10 Inhibition of Bovine Brain Microtubule Assembly in Vitro by Loh, H. H. See Law and Hom, 413 Stypoldione, 493 Lucier, George W. See Thompson, 69 O’Donnell, M. See Rosenkranz, Hoffman, Jacobson, Verlander, Lynch, Gary Kievans, Goodman, and Melmon, 429 See Baudry and Kramer, 229 Olianas, Maria C. See Baudry, Kramer, Fagni, and Recasens, 222 See Onali, Eva, Schwartz, and Costa, 189 See Onali, Schwartz, and Costa, 380 M Onali, Pierluigi Maeda, Kaori. See Kamataki, Yamazoe, Matsuda, Ishii, and Kato, Eva, Carola, Olianas, Maria C., Schwartz, Joan P., and Costa, 146 Erminio. In GH3 Pituitary Cells, Acetyicholine and Vasoactive Makar, A. B., and Tephly, T. R. Effect of Nitrous Oxide and Methi- Intestinal Peptide Antagonistically Modulate Adenylate Cyclase, onine Treatments on Hepatic S-Adenosylmethionine and Meth- Cyclic AMP Content, and Prolactin Secretion, 189 ylation Reactions in the Rat, 124 Olianas, Maria C., Schwartz, Joan P., and Costa, Erminio. M#{228}ntyl#{228},Eero. See Ahotupa, 464 Involvement of a High-Affinity GTPase in the Inhibitory Coupling Marcus, Craig. See Murray, Wilkinson, and Dub#{233},129 of Striatal Muscarmnic Receptors to Adenylate Cyclase, 380 Matsuda, Yasushi. See Kamataki, Maeda, Yamazoe, Ishii, and Kato, 146 P Matthysse, Steven. See Froimowitz, 243 Palacios, Jose M. See Zarbin, Wa,nsley, and Kuhar, 341 Mauger, Jean-Pierre. See Sladeczek and Bockaert, 392 Palatim, P. The Interaction between Full and Partial Inhibitors Acting McGwire, Joan B. See Flaim, Jefferson, and Rannels, 277 on a Single Enzyme: A Theoretical Analysis, 30 McKee, Susan A. See Fyfe and Keller, 316 Parsons, Stanley M. See Anderson and King, 48, 55 Melmon, K. L. See Rosenkranz, Hoffman, Jacobson, Verlander, Patel, Nutan T. See Denney, Fritz, Widen, and Abell, 60 Klevans, O’Donnell, and Goodman, 429 Patierno, Steven R. See Evans, Wang, Cantoni, and Costa, 77 Meunier, Jean-Claude, Kouakou, Yao, Puget, Main, and Mois- Philpot, Richard M. See Robertson, Serabjit-Singh, and Croft, 156 and, Christiane. Multiple Opiate Binding Sites in the Central Pittman, Randall N., and Molinoff, Perry B. Interactions of Full Nervous System of the Rabbit: Large Predominance of a Mu and Partial Agonists with Beta-Adrenergic Receptors on Intact L6 Subtype in the Cerebellum and Characterization of a Kappa Sub- Muscle Cells, 398 type in the Thalamus, 23 Pochet, R. See Waelbroeck, Taton, Delhaye, Chatelain, Camus, Le- Miller, Jerry R., Silver, Paul J., and Stull, James T. The Role of clerc, De Smet, Robberecht, and Christophe, 174 Myosin Light Chain Kinase Phosphorylation in Beta-Adrenergic Puget, Main. See Meunier, Kouakou, and Moisand, 23 Relaxation of Tracheal Smooth Muscle, 235 Miller, Mark Steven, Huang, Mou-Tuan, Jeffrey, Alan M., and Conney, Allan H. Betamethasone-Mediated Activation of Bi- Q phenyl 2-Hydroxylation in Rat Liver Microsomes: Studies on Pos- Quist, Eugene E. See Zeleznikar and Drewes, 163 sible Mechanisms, 137 Mintz, Keith P. See Brimoin and Alley, 513 R Moisand, Christiane. See Meunier, Kouakou, and Puget, 23 Rannels, D. Eugene. See Flaim, Jefferson, and McGwire, 277 Molinoff, Perry B. See Pittman, 398 Rauscher, Frank, ifi, Mueller, Gail, and Beerman, Terry. The Mornparler, Richard L. See Bouchard, 109 Effects ofthe Antitumor Protein Auromomycin on HeLa S3 Nuclei: Mueller, Gail. See Rauscher and Beerman, 97 Release of Soluble Chromatin, 97 Mulcahy, Linda S., and Gans, Joseph H. The Fidelity of Mouse Recasens, Max. See Baudry, Kramer, Fagni, and Lynch, 222 Liver Mitochondrial DNA Polymerase following Long-Term Ad- Robberecht, P. ministration of Carbon Tetrachloride, Diethylnitrosamine, or Delhaye, M., Taton, G., De Neef, P., Waelbroeck, M., De Smet, Phenobarbitol, 329 J. M., Leclerc, J. L., Chatelain, P., and Christophe, J. The Murphy, David G. See Fischer and Kawahara, 90 Human Heart Beta-Adrenergic Receptors. I. Heterogeneity of the Murray, Michael, Wilkinson, Christopher F., Marcus, Craig, and Binding Sites: Presence of 50% Beta,-and 50% Beta2-Adrenergic DuInI, Christopher E. Structure-Activity Relationships in the Receptors, 169 Interactions of Alkoxymethylenedioxybenzene Derivatives with See Waelbroeck, Taton, Delhaye, Chatelain, Camus, Pochet, Le- Rat Hepatic Microsomal Mixed-Function Oxidases in Vivo, 129 clerc, De Smet, and Christophe, 174 Roberts, G. C. K. See Barrett, Burgen, and Clore, 443 N Robertson, lain G. C., Serabjit-Smgh, Cosette, Croft, Jane E., Nichol, Charles A. See Duch, Lee, and Edel.stein, 103 and Philpot, Richard M. The Relationship between Increases in Nordstrom, Oie, Alberta, P#{233}teris, Westlind, Anita, Und#{233}n,An- the Hepatic Content of Cytochrome P-450, Form 5, and in the ders, and Bartfai, Tamas. Presynaptic Antagonist-Postsynaptic Metabolism of Aromatic Amines to Mutagenic Products following Agonist at Muscarmnic Cholinergic Synapses: N-Methyl-N-(1- Treatment of Rabbits with Phenobarbital, 156 methyl-4-pyrrolidino-2-butynyl)acetamide, 1 Rosenkranz, R. P., Hoffman, B. B., Jacobson, K. A., Verlander, Nukada, Toshihide M. S., Kievans, L., O’Donnell, M., Goodman, M., and Mehnon, Haga, Tatsuya, and Ichiyama, Arata. Muscarmnic Receptors in K. L. Conjugates of Catecholamines. II. In Vitro and in Vivo 536 AUTHOR INDEX

Rosenkranz, R. P.-Continued Verlander, M. S. See Rosenkranz, Hoffman, Jacobson, Kievans, Pharmacological Activity of N-Alkyl-Functionalized Carboxylic O’Donnell, Goodman, and Melmon, 429 Acid Congeners and Amides Related to Isoproterenol, 429 Vyas, Kamlesh P., van Bladeren, Peter J., Thakker, Dhiren R., Ross, Elliott M. See Florio, 195 Yagi, Haruhiko, Sayer, Jane M., Levin, Wayne, and Jerina, Roth, Robert A. See Wiersma, 300 Donald M. Regioselectivity and Stereoselectivity in the Metabo- 1mm of trans-1,2-Dihydroxy-1,2-dthydrobenz[ajanthracene by Rat S Liver Microsomes, 115

Sayer, Jane M. See Vyas, van Bladeren, Thakker, Yagi, Levin, and W Jerina, 115 Schein, Philip S. See Tew, Erickson, White, Wang, and Hartley-Asp, Wachtel, Ruth E., and Wilson, Wilkie A., Jr. Barbiturate Effects 324 on Acetylcholine-Activated Channels in Aplysia Neurons, 449 Schellenberg, Gerard D., Anderson, Leojean, and Swanson, Phil- Waelbroeck, M. lip D. Inhibition of Na-Ca2 Exchange in Rat Brain by Amiloride, Taton, G., Delhaye, M., Chatelain, P., Camus, J. C., Pochet, R., 251 Leclerc, J. L., De Smet, J. M., Robberecht, P., and Chris- Schultz, G#{252}nter See Aktories and Jakobs, 183 tophe, J. The Human Heart Beta-Adrenergic Receptors. II. Cou- Schwartz, Joan P. pling of Beta-Adrenergic Recptors with the Adenylate Cyclase See Onali, Eva, Olianas, and Costa, 189 System, 174 See Onali, Olianas, and Costa, 380 See Robberecht, Delhaye, Taton, De Neef, De Smet, Leclerc, Cha- Schwartz, Rochelle D., and Kellar, Kenneth J. [3H]Acetylcholine telain, and Christophe, 169 Binding Sites in Brain: Effect of Disulfide Bond Modification, 387 Wamsley, James K. See Zarbin, Palacios, and Kuhar, 341 Seernan, Philip. See Lilly, Fraser, Jung, and Venter, 10 Wang, Ann L. See Tew, Erickson, White, Schein, and Hartley-Asp, Selassie, Cynthia Dias. See Woodson, Ames, Hansch, and Wein- 324 shilboum, 471 Wang, De-Shin. See Evans, Patierno, Cantoni, and Costa, 77 Serabjit-Smgh, Cosette. See Robertson, Croft, and Philpot, 156 Wanwimoiruk, Sompon, Birkett, Donald J., and Brooks, Peter Shannon, MichaeL See Battaglia and Titeler, 409 M. Structural Requirements for Drug Binding to Site II on Human Sharpless, Norman E. See Kador, 521 Serum Albumin, 458 Silver, Paul J. See Miller and Stull, 235 Webster, Leslie T., Jr. See Tracy and Catto, 291 Sladeczek, Fritz, Bockaert, Joel, and Mauger, Jean-Pierre. Dif- Weinshilboum, Richard M. See Woodson, Ames, Selassie, and ferences between Agonist and Antagonist Binding to Alpha,-Ad- Hansch, 471 renergic Receptors of Intact and Broken-Cell Preparations, 392 Westlind, Anita. See Nordstrom, Alberts, Und#{233}n, and Bartfai, 1 Sokolovsky, Mordechai. See Henis, 357 White, Geoffrey. See Tew, Erickson, Wang, Schein, and Hartley- Strosar, Mira. See Eyer and Lierheimer, 282 Asp, 324 Stull, James T. See Miller and Silver, 235 White, Steven J., and Jacobs, Robert S. Effect of Stypoldione on Sturtevant, J. M. See Herbette and Katz, 259 Cell Cycle Progression, DNA and Protein Synthesis, and Cell Swanson, Phiffip D. See Schellenberg and Anderson, 251 Division in Cultured Sea Urchin Embryos, 500 Widen, Steven G. See Denney, Fritz, Patel, and Abell, 60 T Wiersrna, David A., and Roth, Robert A. The Prediction of Benzo[a]pyrene Clearance by Rat Liver and Lung from Enzyme Taton, G. Kinetic Data, 300 See Robberecht, Delhaye, De Neef, Waelbroeck, De Smet, Leclerc, Willdnson, Christopher F. See Murray, Marcus, and Dub#{233},129 Chatelain, and Christophe, 169 Wilson, Leslie. See O’Brien and Jacobs, 493 See Waelbroeck, Delhaye, Chatelain, Camus, Pochet, Leclerc, De Wilson, Wilkie A., Jr. See Wachtel, 449 Smet, Robberecht, and Christophe, 174 Woodson, Lee C., Ames, Matthew M., Selassie, Cynthia Dias, Tephly, T. R. See Makar, 124 Hansch, Corwin, and Weinshilboum, Richard M. Thiopurine Tew, Kenneth D., Erickson, Leonard C., White, Geoffrey, Wang, Methyltransferase: Aromatic Thiol Substrates and Inhibition by Ann L., Schein, Philip S., and Hartley-Asp, Beryl. Cytotoxic- Benzoic Acid Derivatives, 471 ity of Estramustine, a Steroid-Nitrogen Mustard Derivative, Wright, Gregory B., Alexander, R. Wayne, Eckstein, Laurie S., through Non-DNA Targets, 324 and Gimbrone, Michael A., Jr. Characterization of the Rabbit Thakker, Dhiren R. See Vyas, van Bladeren, Yagi, Sayer, Levin, Ventricular Myocardial Receptor for Angiotensin II: Evidence for andJerina, 115 Two Sites of Different Affinities and Specificities, 213 Thayer, Stanley A., and Fairhurst, Alan S. The Interaction of Dihydropyridine Calcium Channel Blockers with Calmodulin and Y Calmodulin Inhibitors, 6 Yagi, Haruhiko. See Vyas, van Bladeren, Thakker, Sayer, Levin, Thompson, Claudia, and Lucier, George W. Hepatic Estrogen and Jerina, 115 Responsiveness: Possible Mechanisms for Sexual Dimorphism, 69 Yamazoe, Yasuchi. See Kamataki, Maeda, Matsuda, Ishii, and Titeler, Milt. See Battaglia and Shannon, 409 Kato, 146 Todaro, Louis J. See Blount, Fryer, and Gilman, 425 Tracy, James W., Catto, Brian A., and Webster, Leslie T., Jr. z Reductive Metabolism of Niridazole by Adult Schistosoma man- soni: Correlation with Covalent Drug Binding to Parasite Macro- Zahler, Warren L. See Forte and Bylund, 42 molecules, 291 Zarbin, Marco A., Palacios, Jose M., Warnsley, James K., and Kuhar, Michael J. Axonal Transport of Beta-Adrenergic Recep- U tors: Antero- and Retrogradely Transported Receptors Differ in Agonist Affinity and Nucleotide Sensitivity, 341 Und#{233}n,Anders. See Nordstrom, Alberts, Westlind, and Bartfai, 1 Zeleznikar, Robert J., Jr., Quist, Eugene E., and Drewes, Lester R. AnAlpha,--Mediated Phosphatidylinositol V Effect in Canine Cerebral Microvessels, 163 van Bladeren, Peter J. See Vyas, Thakker, Yagi, Sayer, Levin, and Ziminsld, T. See Cybuiska, Borowski, and Gary-Bobo, 270 Jerina, 115 Zukin, Suzanne, See Chow, 203 Venter, J. Craig. See Lilly, Fraser, Jung, and Seeman, 10 Zunino, Franco. See Gambetta, Colombo, and Lanzi, 336 MOLECULAR PHARMACOLOGY 24:537-554

CUMULATIVE SUBJECT INDEX’ FOR VOLUMES 23 AND 24

A in heart auricles (human), 24, 174 in pituitary GH3 cells, 24, 189 Acetylcholine inhibition, 24, 195, 380 -activated neuronal channels, barbiturate effects, 24,449 noncoupled with angiotensin II (rabbit), 24, 213 3H-labeled, binding sites in brain (rat), 24, 387 somatostatin inhibition, 24, 183 modulation spermatozoal, effect of forskolin, 24,42 adenylate cyclase in GH3 pituitary cells, 24, 189 testicular, effect of forskolin, 24, 42 cyclic AMP content in pituitary G}L cells, 24, 189 Adipose tissue prolactin secretion in pituitary GH3 cells, 24, 189 content in nonresponsive mice, 24,464 muscarinic, 24, 380 role in hexachlorobiphenyl metabolism (mouse), 24, 464 receptor Adrenal effect of cis-bis-Q (eel), 23, 344 cortex, activation by guanine nucleotides (rat), 23, 369 nicotinic, antibiotic inhibition, 23, 8 medulla, ascorbic acid secretion (bovine), 23, 437 release, 24, 1 medullary cells storage (ray), 24, 48, 55 calcium uptake (bovine), 23, 547 transport catecholamine secretion (bovine), 23, 547 effect of tetraphenylborate (ray), 24, 55 catecholamine secretion (bovine), 23, 671 in synaptic vesicles (ray), 24,48 culture (bovine), 23, 547 Acetylcholinesterase ion flux (bovine), 23, 681 brain (chicken), 23, 717 steroidogenesis, inhibition, 23, 743 red blood cell, monoclonal antibodies (human), 24, 513 Adrenergic receptor ACTH, see Adrenocorticotropic hormone alpha, Activation agonist and antagonist binding, 24, 392 adenylate cyclase, role of calcium and magnesium ions (rat), 23, 369 chiorpromazine antagonism, 23, 67 benzidine, by peroxidases, 23, 766 in cerebral microvessels (dog), 24, 163 oxidation, mechanisms (rat), 24, 137 in pituitary neurointermediate lobe (porcine), 24, 409 Activity postsynaptic, in tracheal smooth muscle (dog), 23, 570 adenylate cyclase, synaptic membranes from striatum (rat), 23, 393 trifluoperazine antagonism, 23, 67 antiparasitic, mridazole (schist’seome), 24,291 turnover in submaxillary glands (rat), 23, 282 aromatic heptaene macrolide antibiotics, on biological and lipidic vas deferens (rat), 23, 359 model membranes, 24, 270 alphar cytocidal, 9-deazaadenosine, in colon carcinoma (human), 24, 309 in intestinal epithelial cells (rat), 23, 228 ionophoretic, 24, 270 postsynaptic, in tracheal smooth muscle (dog), 23, 570 Acyclovir, herpes simplex virus sensitivity, 24, 316 beta Adaptation, cellular, down-regulation and desensitization, 24, 413 agonist affinity (rat), 24, 341 Adenohypophysis agonists, nonselective (human), 24, 169 dopamine receptor (rat), 23, 576 axonal transport (rat), 24, 341 effect of muscarinic antagonists on receptor conformations (rat), 24, in erythrocytes (rat), 24, 174 357 in heart (rat), 24, 174 Adenosine in heart auricles (human), 24, 169 deaminase, lymphocytic (mouse), 23, 165 in reticulocytes (rat), 24, 174 interaction with stimulatory ligands, 24, 195 interaction with full and partial agonists, 24, 398 S-Adenosyhnethionine nucleotide sensitivity (rat), 24, 341 elevation (rat), 24, 124 on intact L6 muscle cells, 24, 398 hepatic tracheal smooth muscle, 24, 235 effect of methionine (rat), 24, 124 beta2, in heart (human), 24, 174 effect of nitrous oxide (rat), 24, 124 Adrenocorticotropic hormone, mechanism of action (rat), 23, 369 Adenylate cyclase Affinity activity oxotremorine analogues, for ileal muacarinic receptors (guinea pig), in cultured flbroblasts, 23, 648 23, 17 in synaptic membranes from striatum (rat), 23, 393 phenyl N-methyl carbamates, quantum mechanical study, 24, 436 adrenal cortex, activation by guanine nucleotides (rat), 23, 369 Aflatoxin B,, metabolism to promutagen (rat), 24, 146 anterior pituitary (rat), 23, 576 Aggregation, platelet, inhibition by S-nitrosothiols (human), 23, 653 catalytic component, 24, 195 Aging coupling to striatal muscarinic receptors, 24, 380 effect on cytochrome P-450 isoenzymes (rabbit), 23, 244 D2 dopamine receptor binding (rat), 23, 576 effect on drug-metabolizing enzymes (rabbit), 23, 244 dopamine inhibition (rat), 23, 576 Agonist GTP-dependent activity, 23, 648 affinity for beta-adrenergic receptors (rat), 24, 341 heart, coupling with beta-adrenergic receptors (human), 24, 174 beta-adrenergic full, in heart (human), 24, 174 I Boldface numbers indicate appropriate volume; lightface numbers nonselective (human), 24, 169 indicate pagination. partial, in heart (human), 24, 174

0026-895X/83/060537-18$02.00/0 Copyright © 1983 by The American Society for Pharmacology and Experimental Therapeutics. 537 All rights of reproduction in any form reserved. 538 SUBJECT INDEX

Agonist-Continued 2-Aminofluorine beta2-selective, binding in heart (human), 24, 169 cytochrome P-450 induction (rat), 24, 146 binding mutagenic products (rabbit), 24, 156 in caudate nucleus (porcine), 24, 366 Aminoglycoside antibiotics, 3-dimensional structure-activity relation- to alpha1-adrenergic receptors, 24, 392 ship, 23, 127 to anterior pituitary (rat), 23, 44 2-Amino-6-methyl-dipyrido(1,2-a:3’,2’-d)imidazole, polychlorinated bi- temperature dependence, 24, 392 phenyl hydroxylation (rat), 24, 146 concentration jumps (eel), 23, 344 3-Amino-1-methyl-5H-pyrido(4,3-b)indole, polychiorinated biphenyl differential effects, 24, 398 hydroxylation (rat), 24, 146 full, interaction with beta-adrenergic receptors, 24, 398 p-Aminophenol, oxidation, catalysis, 23, 461 -induced changes in nucleotide synthesis and degradation, 23, 384 , microsomal metabolism (rat), 23, 748 kappa, in thalamus (rabbit), 24, 23 Amphibian, myelinated axon, 23, 519 mu, in cerebellum (rabbit), 24, 23 Amylobarbitone, oxidation (human), 23, 474 muscarinic Analogue ileal (guinea pig), 23, 17 cystosine arabinoside, antileukemic activity, 23, 175 partial (guinea pig), 23, 17 dCMP (human), 23, 159 opiate 2’-deoxycytidine, antileukemic activity, 23, 175 in cerebellum (rabbit), 24, 23 formation, NAD, 23, 534 in thalamus (rabbit), 24, 23 oxotremorine, 24, 1 partial, interaction with beta-adrenergic receptors, 24, 398 ileal muscarinic receptors (guinea pig), 23, 17 postsynaptic substance P, dissociation constant (guinea pig), 23, 558 at muscarinic cholinergic synapses, 24, 1 uridine, transport in lymphoblastoid cells (human), 23, 153 muscarirnc, 24, 1 Anemia, sickle cell, hemoglobin solubiity, 23, 100 -receptor, high-affinity states (bovine), 23, 295 Anesthetic, local, effect on binding and depolarization in cerebral cortex semirigid, effect on nicotinic acetylcholine receptors (frog), 23, 337 (guinea pig), 23, 350 AH5183, see 2-(4-Phenylpiperidino)cyclohexanol Angiotensin II Albumin noncoupled with adenylate cyclase (rabbit), 24, 213 human serum receptor site II binding site, 24, 458 regulation, cations and guanine nucleotides (rabbit), 24, 213 structural requirements for binding, 24, 458 ventricular myocardial (rabbit), 24, 213 production, liver, effect of halothane (rat), 24, 277 Aniline, microsomal p-hydroxylation, 23, 213 Alcohol, see also Ethanol Anion microsomal p-hydroxylation of aniline, 23, 213 effect on acetylcholine transport (ray), 24, 55 Aldose reductase transport, inhibitors, 23, 92 inhibitor site, pharmacophor requirements, 24, 521 Ansamycins, structure-activity relationship, 23, 133 inhibitors, design, 24, 521 Antagonism Alkaloid dynorphin ergot, interaction with D-2 dopamine receptors (bovine), 23, 585 f-chlornaltrexamine, 23, 36 harmala, ionization, 23, 614 naloxone, 23, 36 Alkoxymethylenedioxybenzene, derivatives, interactions with hepatic summation of inhibitory effects, 24, 30 microsomal mixed-function oxidases (rat), 24, 129 Antagonist N-Alkyl-functionalized congeners and amides related to isoproterenol, y-aminobutyric acid, binding in brain (rat), 23, 326 24, 429 beta-adrenergic Allosteric interactions in brain (rat), 23, 326 in heart (human), 24, 174 Amine nonselective (human), 24, 169 aromatic beta,-selective, binding in heart (human), 24, 169 metabolism in liver (rabbit), 24, 156 binding mutagenesis (rabbit), 24, 156 to alpha,-adrenergic receptors, 24, 392 bound, chromaffin granules (bovine), 23, 431 to anterior pituitary (rat), 23, 44 Amide, carboxylic acid, related to isoproterenol, 24, 429 calmodulin Amiloride, inhibition of Na-Ca2 exchange in brain (rat), 24, 251 effect on Ca2 uptake in pentoneal macrophages (guinea pig), 23, Amino acid 78 adduct, thioacetamide S-oxide (rat), 23, 219 effect on smooth muscle (bovine), 23, 665 receptor, acidic, in hippocampus, 24, 222, 229 folate, tetrahydrobiopterin, 24, 103 2-Aminoanthracene, mutagenic products (rabbit), 24, 156 muscarinic 4-Aminobiphenyl, cytochrome P-450 induction (rat), 24, 146 benzilates and tropates, 24, 357 Aminobutyric acid effect on receptor conformations in adenohypophysis (rat), 24, 357 antagonist, binding in brain (rat), 24, 326 ileal (guinea pig), 23, 17 binding, group-selective reagent modification, 23, 52 presynaptic receptor at muscarinic cholinergic synapses, 24, 1 brain-specific binding (rat), 23, 326 muscarinic, 24, 1 -chloride ion channel complex (rat), 23, 315 regulatory, iododeoxyuridine metabolism, 23, 709 interactions with benzodiazepine receptor (rat), 23, 315 Ro 15-1788, effect on benzodiazepine receptors (rat), 23, 289 y-Aminobutyric acid-A, brain-specific binding sites (rat), 23, 326 Anthracycline antibiotics, binding in liver (rat), 24, 336 5’-Amino-5’-deoxythymidine Antibiotic(s) modulation of iododeoxyuridine cytotoxicity, 23, 709 aminoglycoside, 3-dimensional structure relationship, 23, 127 modulation of iododeoxyuridine metabolism, 23, 709 anthracydline, binding in liver (rat), 24, 336 preferential inhibition of phosphorylation, 24, 90 antitumor protein, 23, 500 SUBJECT INDEX 539

aromatic heptaene macrolide Benz[a}anthracene, induction of cytochrome P-450 in fibroblasts activity on biological and lipidic model membranes, 24, 270 (mouse), 23, 198 electric charge, 24, 270 Benzidine, activation by peroxidases, 23, 766 effect on nicotinic acetylcholine receptor, 23, 8 20 a-Benzoate, binding in cerebral cortex (guinea pig), 23, 350 holo-, chromophore, 24, 97 Benzodiazepine Antibody, monoclonal antagonist, Ro 15-1788 (rat), 23, 289 cholinesterases (human), 24, 513 binding molecular activity (human), 24, 60 group-selective reagent modification, 23, 52 monoamine oxidase (human), 24,60 sites, water solubility (rat), 23, 310 Antidepressant endogenous inhibitor competition in vivo (rat), 23, 310 brain, receptors, 23, 594 receptor effect on binding, 23, 629 binding, extraction in distilled water (rat), 23, 310 Antidiarrheal agents, effect on intestinal epithelial cells (rat), 23, 228 binding kinetics (rat), 23, 289 Antimycin A, effects on parotid gland (rat), 23, 71 brain-specific (rat), 23, 326 Antipyrine, oxidation (human), 23, 474 conformational change (rat), 23, 289 Antitumor drug, a-1,3,5-triglycidyl-s-triazinetrione, 23, 182 endogenous inhibitor(s) (rat), 23, 310 Antitussive, effect on dextromethorphan binding, 23, 629 interactions with y-aminobutyric acid and barbiturate receptor Antiviral agents, cytotoxicity, 24, 90 sites (rat), 23, 315 Antiviral mechanism ligand interactions, 24, 425 acyclovir, 24, 316 subtypes (rat), 23, 315 (E)-5-(2-bromovinyl)-2’-deoxyuridine, 24, 316 1,4-Benzodiazepines, conformational recognition of receptor, 24, 425 Anxiolytic, binding in brain (rat), 23, 326 Benzoic acid, derivatives, effect on thiopurmne methyltransferase, 24, Apamin, effect in yes deferens (guinea pig), 23, 409 471 Apoprotein, neocarzinostatin binding, 23, 500 Benzo[a]pyrene Aromatic sulihydryl methyl acceptors, 24, 471 clearance, prediction (rat), 24, 300 Aryl hydrocarbon hydroxylase cytochrome P-450 induction (rat), 24, 146 cytochrome P-450 (rat), 24, 129 liver metabolism (rat), 24, 300 induction in fibroblasts (mouse), 23, 198 lung metabolism (rat), 24, 300 reconstituted system (guinea pig), 23, 258 metabolism, product inhibition, 23, 735 Ascaris suum, glycogen metabolism, cyclic AMP-mediated regulation, 23, 378 metabolism, in hepatic microsomes (rat), 23, 748 Ascorbic acid sequential oxidation (rat), 23, 748 compartmentalization (bovine), 23, 437 N-Benzylethyl-a-phenylnitrone, microsomal metabolism (rat), 23, 748 secretion (bovine), 23, 437 Betamethasone by chromaffin cells (bovine), 23, 437 activation of monooxygenases (rat), 24, 137 Atenolol, binding in heart (human), 24, 169, 174 -mediated activation of biphenyl 2-hydroxylation (rat), 24, 137 ATP, 3H-labeled Binding binding, 23, 1 [3H]acetylcholine in brain (rat), 24, 387 divalent ion-specific binding (rabbit), 23, 1 agonist ATPase, divalent ion, 23, 1 temperature dependence, 24, 392 Atrium, phosphatidylinositol metabolism (mouse), 24, 351 to alpha,-adrenergic receptors, 24, 392 Auricle, heart, beta-adrenergic receptors (human), 24, 169, 174 y-aminobutyric acid, group-selective reagent modification, 23, 52 Auromomycin antagonist, to alpha,-adrenergic receptors, 24, 392 DNA damage, 24, 97 anthracycline antibiotics, in liver (rat), 24, 336 effect on HeLa S nuclei, 24, 97 3H-ATP, 23, 1 Axon, myelinated benzodiazepine, group-selective reagent modification, 23, 52 amphibian, 23, 519 1,4-benzodiazepines, conformational recognition of receptor, 24, 425 effect of scorpion neurotoxins, 23, 519 [S]t-butylbicyclophosphorothionate, to brain-specific sites (rat), 23, Axonal transport, beta-adrenergic receptors (rat), 24, 341 326 5-Azadeoxycytidine, inhibition of DNA methylation, 24, 109 5-Azadeoxycytidine 5’-triphosphate in brain (mouse, rat), 23, 600 DNA methylase, 24, 109 in platelets (human), 23, 600 DNA polymerase, 24,109 covalent 6-Azauridine, transport, in lymphoblastoid cells (human), 23, 153 4-dimethylaminophenol, to hemoglobin (human), 24, 282 mechanism, 24, 182 B site in hemoglobin (human), 24, 282 Barbiturate cytochrome P-450, mechanism, 23, 213 binding dextromethorphan in brain, 23, 52 effect of antidepressants, 23, 629 in brain (rat), 23, 326 effect of antitussives, 23, 629 effects on acetylcholine-activated neuronal channels, 24, 449 effect of diphenylhydantoin, 23, 629 receptor, interactions with benzodiazepine receptor (rat), 23, 315 effect of noscapine, 23, 629 Batrachotoxin-induced depolarization in cerebral cortex (guinea pig), effect of phenothiazines, 23, 629 23, 350 [3Hdextromethorphan Batrachotoxinin-A, 3H-labeled, binding in cerebral cortex (guinea pig), in brain (guinea pig), 23, 619 23, 350 in brain and liver (guinea pig), 23, 629 BC3H4 cell, agonist and antagonist binding to alpha,-adrenergic recep- , in brain (guinea pig, rat), 23, 619 tore, 24, 392 diazepam, conformation for, 24, 425 540 SUBJECT INDEX

Binding-Continued Brain divalent ion-specific, of 3H-ATP (rabbit), 23, 1 [3H]acetylcholine binding sites (rat), 24, 387 dopamine receptor (bovine), 23, 295 alpha,-adrenergic receptors (porcine), 24, 409 DNA, neocarzinostatin chromophore, 23, 500 antidepressants, receptors, 23, 594 drug carboxylesterases, inhibition (chicken), 23, 717 covalent (schistosome), 24, 291 cocaine binding (mouse, rat), 23, 600 energy-dependent (human), 24, 485 cortex, muscarinic receptors (rat), 24, 357 fatty acid study, 24, 458 dextromethorphan binding (guinea pig), 23, 629 hydrophobic, 24, 324 dopamine receptors (dog, human), 24, 10 structural requirements, 24, 458 [3H]flunitrazepam binding sites, solubility (rat), 23, 310 estramustine, to nuclear matrix, 24, 324 high-affinity dextromethorphan binding sites estrogen, hepatic (rat), 24, 69 regional distribution (guinea pig), 23, 619 ethylketocyclazocine, to neurotumor cells, 23, 486 subcellular distribution (guinea pig), 23, 619 guanine nucleotides medulla-pons, muscarinic receptors (rat), 24, 357 in adrenal membranes (rat), 23, 369 microtubule assembly, inhibition by stypoldione (bovine), 24, 493 role of calcium ion (rat), 23, 369 Na-Ca2 exchange (rat), 24, 251 [3H], 23, 607 nicotinic cholinergic receptor (rat), 24, 387 ion recognition sites, brain-specific (rat), 23, 326 opiate receptor, mu and kappa subtypes (rat), 24, 203 kinetics, benzodiazepine (rat), 23, 289 serotonergic neurons (mouse, rat), 23, 600 ‘9-labeled cobra a-toxin, 23, 8 -specific [35S]t-butylbicyclophosphorothionate binding sites (rat), 23, ligand-receptor interactions (bovine), 23, 585 326 [3H] Bromobenzene metabolism, glutathione (rat), 23, 235 temperature dependence, 23, 60 (E)-5-(2-Bromovinyl)-2’-deoxyuridine, herpes simplex virus sensitivity, to histamine H, receptor, 23, 60 24, 316 [3H]cis-methyldioxolane Butaclamol, conformational properties, 24, 243 in caudate nucleus (porcine), 24, 374 Butylated hydroxyanisole, effect on benzidine oxidation, 23, 766 to guanyl nucleotide-sensitive sites (porcine), 24, 366 t-Butylbicyclophosphorothionate, ‘S-labeled, binding to brain-specific multiple states (bovine), 23, 585 sites (rat), 23, 326 muscarinic receptors, modification by gallamine (rat), 23, 551 t-Butylphosphorothionate, affinity binding (rat), 23, 326 quinazolines, conformation for, 24, 425 -y-Butyrolactone, receptor, computer-assisted modeling, 23, 511 radioligand, tracheal (dog), 23, 570 Butyrylcholinesterase, plasma, monoclonal antibodies (human), 24, 513 Ro 11-2465, 23, 607 C site(s) [3H]acetylcholine (rat), 24, 387 Ca2, see also Calcium beta-adrenergic receptors in heart (human), 24, 169, 174 -dependent cyclic AMP accumulation, regulation in pituitary tumor benzodiazepine, water solubiity (rat), 23, 310 cells (rat), 23, 399 cardiac muscarinic receptor (rat), 24, 15 intracellular, accumulating system in peritoneal macrophages (guinea kappa opiate, regional distribution (rabbit), 24, 23 pig), 23, 78 opiate, in central nervous system (rabbit), 24, 23 metabolism, in pituitary tumor cells (rat), 23, 399 serotonin,, 23, 594 mobilization, in GH3 cells (rat), 23, 399 [3H]spiroperidol -Na, exchange in brain (rat), 24, 251 in striatum (rat), 23, 303 transport in brain (rat), 24, 251 thermodynamics (rat), 23, 303 uptake in peritoneal macrophages (guinea pig), 23, 78 , chromaffin granules (bovine), 23, 431 Cadmium [3H]tetrahydrotrazodone, 23, 594 growth inhibition, 24, 77 [3H]yohimbine (rat), 23, 228 -resistant cells, 24, 77 Biochemical analysis Calcium, see also Ca2 in study of effect of chlorpromazine (human), 23, 771 -activated potassium conductance (guinea pig), 23, 409 in study of erythrocyte membrane protein (human), 23, 771 channel blockers, 24, 6 Biosynthesis, tetrahydrobiopterin, 24, 103 effect on beating in heart cells in culture, 23, 417 Biotransformation, phenol, by liver microsomes (rat), 23, 453 exchange, in heart cells, 23, 417 Biphenyl ion hydroxylation role in adenylate cyclase activation (rat), 23, 369 cumene hydroperoxide (rat), 24, 137 role in guamne nucleotide binding (rat), 23, 369 Km and Vmax (rat), 24, 137 mobilization in parotid gland (rat), 23, 71 2-hydroxylation pump, inhibition by ouabain (bovine), 23, 681 betamethasone-mediated (rat), 24, 137 release, myocardial cell membrane, 23, 417 mechanisms (rat), 24, 137 uptake polychlorinated, induction of high-spin form of cytochrome P-450 in adrenal medullary cells (bovine), 23, 547 (rat), 24, 146 myocardial cell membrane, 23, 417 cis-Bis-Q, See cis-3,3’-Bis-[a-(trimethylammonium)methyl]azobenzene Calmodulin cis-3,3’-Bis-[a-(trimethylammonium)methyljazobenzene, purification antagonist and properties, 23, 344 effect on Ca2 uptake in peritoneal macrophages (guinea pig), 23, Bladder, urinary 78 divalent ion-specific binding of 3H-ATP (rabbit), 23, 1 effect on smooth muscle (bovine), 23, 665 smooth muscle (rabbit), 23, 1 effect Blood flow, benzo[a]pyrene clearance (rat), 24, 300 in tracheal smooth muscle, 24, 235 Bond, disulfide, effect on [3H]acetylcholine binding (rat), 24, 387 on Ca2 uptake in peritoneal macrophages (guinea pig), 23, 78 SUBJECT INDEX 541

inhibitors, interaction with calcium channel blockers, 24, 6 cytocidal activity of 9-deazaadenosine (human), 24, 309 interaction with calcium channel blockers, 24, 6 effect of sangivamycin (human), 24, 509 Calorimetry, model membranes, partitioning, 24, 259 HT-29, in vitro translation of mRNA (human), 23, 540 Cannabinoids culture, 23, 486 effects on prostaglandin synthesis (human), 23, 121 division, inhibition (sea urchin), 24, 500 stimulation of arachidonate release (human), 23, 121 epithelial, intestinal, alpha2-adrenergic receptor (rat), 23, 228 Cannabis, effect on prostaglandin synthesis (human), 23, 121 erythrocyte, monoclonal antibodies to acetyicholinesterase (human), Carbamyicholine, effect on Na permeability, 23, 8 24, 513 Carbinolamine, intermediate, in N-demethylation reactions, 23, 758 5-fluorouradil activity, 23, 190 Carbon tetrachloride folate cofactor pools, 23, 190 effect of long-term administration on hepatic mtDNA polymerase heart (mouse), 24, 329 in culture, effect of calcium on beating, 23, 417 liver regeneration after treatment (mouse), 24, 329 in culture, effect of halothane on beating, 23, 417 Carboxylesterase, brain (chicken), 23, 717 HeLa, DNA metabolism, 23, 171 Carboxylic acid HeLa S3 amides, related to isoproterenol, 24,429 effects of auromomycin, 24,97 congeners, related to isoproterenol, 24, 429 nuclear chromatin, 23, 493 Carboxymethylation, protein, nitrous oxide (rat), 24, 124 hepatoma Carcinogenesis, polycycic aromatic hydrocarbons (rat), 24, 115 variant, glucocorticoid-inducible gene (rat), 23, 779 Carcinogenicity wild-type, glucocorticoid-inducible gene (rat), 23, 779 2,4-dideuterioestradiol (hamster), 23, 278 herpes simplex virus-infected, 24, 90 2-fluoroestradiol (hamster), 23, 278 intact 4-fluoroestradiol (hamster), 23, 278 agonist and antagonist binding to alpha,-adrenergic receptors, 24, Carcinoma, colon 392 cell culture (human), 24, 309 dopamine receptor binding on (bovine), 23, 295 cytocidal activity of 9-deazaadenosine (human), 24, 309 isolated effect of 5-fluorouracil and 5-fluorouridine (human), 23, 540 adrenal medulla (bovine), 23, 671 effect of sangivamycin on cells (human), 24, 509 effect of ouabain (bovine), 23, 681 Catalysis lymphoblastoid, transport of uridine and 6-azauridine (human), 23, N-demethylation reactions, 23, 758 153 4-hydroxylation of (human), 23, 474 549 lymphoma, cyc and H21a variants, 24, 183 Catalytic component, adenylate cyclase, 24, 195 mammalian, cultured, nucleoside transport, 24, 479 Catechol formation in liver (rat), 23, 453 muscle, L6 Catecholamine intact, 24, 398 carrier, chromaffin granules (bovine), 23, 431 interactions offull and partial agonists with beta-adrenergic recep- conjugates, 24, 429 tors, 24, 398 ionization, chromaffin granules (bovine), 23, 431 NCB-20 hybrid, ethylketocyclazocine binding, 23,486 secretion (bovine), 23, 437 neoplastic, cultured, transport activity, 24, 479 in adrenal medullary cells (bovine), 23, 547, 671, 681 neuroblastoma x glioma NG1O8-15 hybrid, opiate regulation of cyclic ouabain stimulation (bovine), 23, 671 AMP levels, 23, 26 storage vesicle, chromaffin cell (bovine), 23, 437 pituitary, GH3 Cation adenylate cyclase, 24, 189 effect cyclic AMP content, 24, 189 on angiotensin H receptor (rabbit), 24, 213 prolactin secretion, 24, 189 on dextromethorphan binding (guinea pig), 23, 619 sickle on [3H]cis-methyldioxolane binding to guanyl nucleotide-sensitive hemoglobin solubility, 23, 100 sites (porcine), 24, 366 2-imidazoline treatment (human), 23, 731 divalent survival, after exposure to mercury and X-rays, 24,84 receptor in salivary gland membrane (rat), 23, 563 Central nervous system, multiple opiate binding sites (rabbit), 24, 23 regulation of substance P binding in salivary membranes (rat), 23, Centruroides sculpturatus, venom neurotoxins, 23, 519 563 Cerebellum Caudate nucleus, muscarinic receptor (porcine), 24, 366, 374 membranes (rabbit), 24, 23 Cell mu opiate agonists (rabbit), 24, 23 adrenal medullary Cerebral cortex calcium uptake (bovine), 23, 547 [3H]batrachotoxinin-A binding (guinea pig), 23, 350 catecholamine secretion (bovine), 23, 547, 671 20a-benzoate binding (guinea pig), 23, 350 culture (bovine), 23, 547 microvessels effect of ouabain (bovine), 23, 671, 681 alpha,-adrenergic receptor (dog), 24, 163 BC3}L, agonist and antagonist binding to alpha,-adrenergic recep- phosphatidylinositol effect (dog), 24, 163 tors, 24, 392 Chemotherapy broken preparation, agonist and antagonist binding to alpha,-adre- implications (human), 23, 159 nergic receptors, 24, 392 malaria, 23, 92 C3H/1OT1/2, cytochrome P-450 induction (mouse), 23, 198 Chinese hamster ovary cell, tiazofurin inhibition, 23, 534 cadmium-resistant, 24, 77 Chloramphenicol Chinese hamster ovary, tiazofurin inhibition, 23, 534 cytochrome P-450 inhibition (rat), 23, 445 chromaffin, ascorbic acid secretion (bovine), 23, 437 effect on hepatic cytochrome P-450 (rat), 23, 445 colon carcinoma Chloride, ion channel-y-aminobutyric acid complex (rat), 23, 315 culture (human), 24,309 /3-Chlornaltrexamine, dynorphin antagonism, 23,36 542 SUBJECT INDEX

Chlorpromazine Convulsants, cage (rat), 23, 326 antagonism, alpha,-adrenergic effects, 23, 67 Copper, growth inhibition, 24, 77 effect on proteins in erythrocyte membranes (human), 23, 771 Coronary artery, phosphodiesterase inhibitors (bovine), 23, 424 Cholera toxin, effect on GTPase activity in striatal membranes (rat), Covalent binding, protein (rat), 23, 219 24, 380 Cross-linking, intramolecular, 24, 282 Cholesterol Crystal structure, diphenylhydantoin-9-ethyladenine complex, 23, 273 side-chain cleavage, 23, 743 Crystallography, X-ray, conformation of neuroleptics, 24, 243 synaptic membrane content (mouse), 23, 86 Culture Cholinergic receptor, nicotinic, in brain (rat), 24, 387 cell, 23, 486 Cholinergic synaptic vesseLs (ray), 24, 55 adrenal medullary (bovine), 23, 547 acetyicholine transport (ray), 24, 48 colon carcinoma (human), 24, 309 Cholinesterase fibroblasts, adenylate cyclase activity, 23, 648 immunochemical comparisons (human), 24, 513 heart, beating, 23, 417 inhibitors, structure-activity relationships, 24, 436 neoplastic, transport activity, 24, 479 monoclonal antibodies (human), 24, 513 Pla.smodium falciparum, growth suppression in vitro, 23, 92 Cholinolytic, presynaptic (ray), 24, 48 Cumene hydroperoxide, biphenyl hydroxylation (rat), 24, 137 Chromaffin cell Cyclic AMP adrenomedullary, ascorbic acid secretion (bovine), 23, 437 accumulation primary culture (bovine), 23, 437 Ca2 regulation in GH3 cells (rat), 23, 399 Chromaffin granules, catecholamine carrier (bovine), 23, 431 in epithelial cells (rat), 23, 228 Chromatin in GH3 cells (rat), 23, 399 HeLa 53 nuclei, effects of neocarzinostatin, 23, 493 activity in cultured fibroblasts, 23, 648 single-strand breaks, linker, 23, 493 Ca2-dependent accumulation, regulation in pituitary tumor cells soluble, release, 24, 97 (rat), 23, 399 Chromatography, high-performance liquid, purification of cis-bis-Q cellular, opiate regulation, 23, 26 (eel), 23, 344 content in pituitary GH3 cells, 24, 189 Chromophore coronary artery cells (bovine), 23, 424 degradation of chromatin, 23, 493 -dependent protein kinase, 24, 235 neocarzinostatin, binding to DNA, 23, 500 alteration (rat), 23, 641 nonprotein, 23, 500 Type I (rat), 23, 641 Circular dichroism, neocarzinostatin chromophore, 23, 500 Type II (rat), 23, 641 Clearance, benzo[a]pyrene, prediction (rat), 24, 300 -dependent polyamine enzymes, alteration (rat), 23, 641 Cleavage, side-chain, cholesterol, 23, 743 metabolism, muscarinic cholinergic receptor-mediated, 23, 384 Clone, BC3H-1 muscle cell line, 23, 8 regulation of glycogen metabolism (Ascaris), 23, 378 , effect on cyclic AMP in intestinal epithelial cells (rat), 23, tracheal smooth muscle, 24, 235 228 Cyclic GMP Cocaine accumulation (human), 23, 653 binding coronary artery cells (bovine), 23, 424 in brain (mouse, rat), 23, 600 heme stimulation (human), 23, 653 in platelets (human), 23, 600 muscarinic stimulation, 24, 1 N-demethylation (mouse), 23, 482 Cyclosporin A, lymphocyte sensitivity, 23, 703 metabolism (mouse), 23, 482 Cysteine conjugate ,8-lyase (rat), 23, 761 toxicity (mouse), 23, 482 Cytochalasin B, effect on 3-O-methyl-D-glucose in isolated hepatocytes Colon (rat), 23, 141 carcinoma, cytocidal activity of 9-deazaadenosine (human), 24, 309 Cytochrome carcinoma cells P-448, 3-methylcholanthrene-inducible (rat), 23, 252 culture (human), 24, 309 P-450 effect of 5-fluorouracil and 5-fluorouridine (human), 23, 540 activation (rat), 24, 137 effect of sangivamycin (human), 24, 509 aryl hydrocarbon hydroxylase (rat), 24, 129 Complex -dependent monooxygenases, destruction (mouse, rat), 23, 206 diphenylhydantoin-9-ethyladenine, crystal structure, 23, 273 epoxidation of benzo-ring diol epoxides (rat), 24, 115 hydrogen-bonded, crystal structure, 23, 273 forms 2, 4, and 5 (rabbit), 24, 156 Complexation, metal, with rifamycins, 23, 133 form 5, effect of f3-naphthoflavone (rabbit), 24, 156 Computer-assisted modeling hepatic (rabbit), 24, 156 y-butyrolactone receptor, 23, 511 hepatic, catalytic characterization (rat), 24, 146 picrotoxinin receptor, 23, 511 hepatic, N-demethylation, 23, 758 Conformation hepatic, N-demethylation of cocaine (mouse), 23, 482 butaclamol, 24, 243 hepatic, 4-hydroxylation catalysis (human), 23, 474 fortimicins, 23, 127 hepatic, immunochemical quantitation (rat), 24, 146 isobutaclamol, 24, 243 hepatic, in benzo[a]pyrene clearance (rat), 24, 300 receptor, adenohypophyseal, effect of muscarinic antagonists (rat), hepatic, isozymes (rabbit), 24, 156 24, 357 hepatic, isozymes (rat), 23, 265, 748 sodium rifamycin SV, 23, 133 hepatic, 3-methylcholanthrene-induced (guinea pig), 23, 258 Conformational change, benzodiazepine receptors (rat), 23, 289 hepatic, phenol metabolism (rat), 23, 453 Conformer, biologically active, 24, 243 hepatic, role in N-demethylation, 23, 758 Congener, carboxylic acid, related to isoproterenol, 24, 429 hepatic, suicide inactivation (rat), 23, 445 Conjugate, catecholamine, 24, 429 hepatocytic (rat), 23, 235 Contraction, smooth muscle, alpha-adrenergic (dog), 23, 570 high-spin form (rat), 23, 146 SUBJECT INDEX 543

induction in C3H/1OT1/2 fibroblasts (mouse), 23, 198 Dexamethasone, effect on 3-O-methyl-D-glucose uptake in isolated isoenzymes, induction and aging (rabbit), 23, 244 hepatocytes (rat), 23, 141 isozymes (rabbit), 24, 156 Dextromethorphan binding isozymes (rat), 23, 748 effect of antidepressants, 23, 629 mechanism of binding to, 23, 213 effect of antitussives, 23, 629 N-oxidation (mouse), 23,482 effect of diphenylhydantoin, 23,629 phenobarbital induction (rat), 23, 265 effect of noscapine, 23, 629 purification (guinea pig), 23, 258 effect of phenothiazines, 23, 629 pulmonary, in benzo[a]pyrene clearance (rat), 24, 300 Dextromethorphan binding quantitation (rabbit), 23, 244 high-affinity reduction complex (rat), 23, 467 in brain, 23, 629 renal, localization (mouse, rat), 23, 206 in brain (guinea pig), 23, 619 substrate specificity (human), 23, 474 Dextrorphan binding, in brain (guinea pig), 23, 619 xylene induction (rat), 23, 265 Diabetes, complications, control, 24, 521 P-450c, active site (rat), 24, 115 Dialysis, equilibrium, in study of drug binding, 24,458 P-450 Diazepam -dependent cholesterol cleavage, 23, 743 conformation for binding, 24, 425 inhibition, 23, 743 effect on [3H}flunitrazepam binding sites (rat), 23, 310 Cytosine arabinoside, analogues, antileukemic activity, 23, 175 2’,S’-Dideoxyadenosine, interaction with stimulatory ligands, 24, 195 Cytotoxicity, see also Toxicity 2,4-Dideuterloestradiol antagonism, 24,90 carcinogenicity (hamster), 23, 278 estramustine, 24, 324 estrogenicity (hamster), 23, 278 iododeoxyuridine, 23, 709 Diethylnitrosamine mercury (II), 24, 84 effect of long-term administration on hepatic mtDNA polymerase 3-methylcholanthrene metabolites (mouse), 23, 198 (mouse), 24, 329 X-rays, 24, 84 oval cell proliferation after long-term treatment (mouse), 24, 329 Diffusion, accelerative exchange (human), 23, 146 D Dihydrofolate reductase Daunorubicin-binding protein from liver (rat), 24, 336 hepatic dCMP effects of methotrexate (rat), 23, 724 analogues (human), 23, 159 effects of nitrous oxide (rat), 23, 724 deaminase (human), 23, 159 inhibitors, 24, 103 Deaminase Dihydropyridine, calcium channel blockade, 24, 6 adenosine, lymphocytic (mouse), 23, 165 trans-1,2-Dihydroxy-1,2-dihydrobenz[a]anthracene, metabolism (rat), dCMP (human), 23, 159 24, 115 deoxycytidylate, substrate and regulator specificity (human), 23, 159 4-Dimethylaminophenol, covalent binding to hemoglobin (human), 24, 9-Deazaadenosine 282 cytocidal activity in colon carcinoma (human), 24, 309 Dimorphism, sexual, mechanisms (rat), 24,69 effects on nucleic acids in colon carcinoma (human), 24, 309 Diphenyihydantoin effects on protein synthesis in colon carcinoma (human), 24, 309 effect on dextromethorphan binding, 23, 629 7-Deaza-7-carboxamidoadenosine, see Sangivamycin 9-ethyladenine complex, crystal structure, 23, 273 Deazapterin, inhibition of (bovine), 23, 104 Dissociation constant Debrisoquine, 4-hydroxylation (human), 23, 474 determination by pharmacological procedures (guinea pig), 23, 558 Deethylation, ethoxycoumarmn (rat), 23, 235 substance P (guinea pig), 23, 558 Degradation, chromatin substance P analogues (guinea pig), 23, 558 by chromophore, 23, 493 Distribution, electron, in tetramethylammonium ion, 24, 443 by neocarzinostatin, 23, 493 Disulfide bond, effect on [3H]acetylcholine binding (rat), 24, 387 Demethylation, mechanism (mouse), 23, 482 DNA N-Demethylation binding, neocarzinostatin chromophore, 23, 500 carbinolamine intermediate, 23, 758 dihydriol oxide modifications, 23, 735 cocaine (mouse), 23,482 effect on microsomal benzo[a]pyrene metabolism, 23, 735 cytochrome P450-catalyzed, 23,758 metabolism, in HeLa cells, 23, 171 Denervation, effect on hippocampal receptors, 24, 229 methylase, inhibition by 5-azadeoxycytidine, 24, 109 2’-Deoxycoformycin, toxicity in spleen lymphocytes (mouse), 23, 165 non-targets, cytotoxicity of estramustine, 24, 324 2’-Deoxycytidine, analogues, antileukemic activity, 23, 175 polymerase, 5-azadeoxycytidine 5’-triphosphate, 24, 109 Deoxycytidine kinase, role in antileukemic activity, 23, 175 quinone intercalation, 23, 735 Deoxycytidylate deaminase, substrate and regulator specificity (hu- repair, 24, 84 man), 23, 159 single-strand breaks, 24, 84 Deoxyhemoglobin 5, solubiity, effect of phenylalanine derivatives, 23, synthesis 100 inhibition, 23, 698 Depletion, nonprotein, thiol (schistosome), 24, 291 in lymphocytes (mouse), 23, 165 Depolarization, batrachotoxin-induced, in cerebral cortex (guinea pig), Dopamine 23, 350 fl-hydroxylase Desensitation chromaffin cell (bovine), 23, 437 cyclic AMP metabolism, 23, 384 metabolic clearance rate (rat), 23, 112 intrinsic activity-dependent, homologous, 24, 413 inhibition of adenylate cyclase (rat), 23, 576 Development, acidic amino acid receptors in hippocampus during, 24, receptor 229 adenohypophyseal (rat), 23, 576 544 SUBJECT INDEX

Dopamine-Continued Epoxide hydrolase, hepatic (rat), 24, 115 receptor-Continued Equilibrium dialysis, in study of drug binding, 24, 458 agonist/antagonist interactions (rat), 23, 303 Ergot, alkaloid, interaction with D-2 dopamine receptors (bovine), 23, binding on intact cells (bovine), 23, 295 585 D2, anterior pituitary (bovine), 23, 585 Erythrocyte D2, characterization (rat), 23, 576 acetylcholinesterase, monoclonal antibodies (human), 24, 513 D2, molecular size (dog, human), 24, 10 beta-adrenergic receptors (rat), 24, 174 D2, relationship to other neurotranamitters (dog, human), 24, 10 lysis, induction by aromatic heptaene macrolide antibiotics, 24, 270

D2, S1Z (dog, human), 24, 10 membrane D2, structure (dog, human), 24, 10 anion transport inhibitors, 23, 92 in brain (dog, human), 24, 10 protein, effect of chlorpromazine (human), 23, 771 molecular weight (dog, human), 24, 10 nucleoside transport mechanism, interaction with 2’-halogeno-2’-de- thermodynamics (rat), 23, 303 oxyuridines (human), 23, 146 Down-regulation, agonist-specific, homologous, temperature-depend- Ester, phorbol, tumor-promoting, 23, 703 ent, 24, 413 Esterase, neurotoxic (chicken), 23, 717 Drug Estramustine, cytotoxicity, through non-DNA targets, 24,324 antimitotic, 24, 324 Estrogen antischistosomal, 24, 291 binding, hepatic (rat), 24, 69 binding hepatic responsiveness (rat), 24, 69 covalent (schistosome), 24, 291 receptor, hepatic (rat), 24, 69 energy-dependent (human), 24,485 Estrogenicity fatty acid study, 24, 458 2,4-dideuterioestradiol (hamster), 23, 278 hydrophobic, 24, 324 2-fluoroestradiol (hamster), 23, 278 structural requirements, 24,458 4-fluoroestradiol (hamster), 23, 278 -membrane interactions, 24, 259 Ethanol, see also Alcohol -metabolizing enzymes, hepatic microsomal (rabbit), 23, 244 chronic treatment, effect on synaptic membrane order (mouse), 23, modified sensitivities, herpes simplex virus, 24, 316 86 oxidation, polymorphism (human), 23, 474 in vitro effects on synaptosomal membrane order (mouse), 23, 86 resistance, mechanism (human), 24, 485 Ethoxycoumarin, deethylation (rat), 23, 235 Dynorphin 9-Ethyladenine-diphenylhydantoin complex, crystal structure, 23, 273 $-chlornaltrexamine antagonism, 23,36 Ethylketocyclazocine, 3H-labeled, binding to neurotumor cells, 23, 486 receptor N-Ethylmaleimide, effects on [3H}cis-methyldioxolane binding to ileum (guinea pig), 23, 36 guanyl nucleotide-sensitive and insensitive sites (porcine), 24, vas deferens (mouse), 23, 36 374 spare receptor fraction, potency, 23, 36 Etorphine, 3H-labeled, opiate inhibition of binding (rabbit), 24, 23 Excitation-secretion coupling, chromaffin cell (bovine), 23, 437 E Exocytosis Electric charge, aromatic heptaene macrolide antibiotics, 24, 270 catecholamine, adrenal medullary cells (bovine), 23, 547 Electric organ chromaffin cell (bovine), 23, 437 acetylcholine transport (ray), 24, 48 acetylcholine transport (ray), 24, 55 F Electron distribution, in tetramethylammonium ion, 24,443 Electron parasnagnetic resonance, in study of ethanol tolerance FAD-containing monooxygenase (mouse), 23, 86 N-demethylation of cocaine (mouse), 23,482 Electron spin resonance N-oxidation (mouse), 23,482 in study of benzidine activation, 23, 766 Fatty acid, in study of drug binding, 24, 458 in study of effect of chiorpromazine (human), 23, 771 Fenmetozole, anti-sickling property (human), 23, 731 in study of erythrocyte membrane protein (human), 23, 771 Fenoterol in study of oxidation ofp-aminophenol, 23, 461 binding in heart (human), 24, 174 Electron transport, enhanced (rat), 24, 137 nonselective beta-adrenergic agonist, binding in heart (human), 24, Electroplaque, Electrophorus, acetylcholine receptors, 23, 344 169 Elution, alkaline, 24,84 Fibroblast Embryo, development, effect of stypoldione (sea urchin), 24, 500 aryl hydrocarbon hydroxylase induction (mouse), 23, 198 Empirical force field, fortimicin, 23, 127 C3H/1OT1/2, cytochrome P.450 induction (mouse), 23, 198 Endoplasmic reticulum, Ca2 transport (guinea pig), 23, 78 cultured, adenylate cyclase activity, 23, 648 Energy pulmonary, prostaglandin synthesis (human), 23, 121 -dependent drug binding (human), 24, 485 Flavonoids, effects on splenocyte cell cultures, 23, 698 -dependent Vinca alkaloid retention (human), 24, 485 Fluorescence, neocarzinostatin chromophore, 23, 500 Enzyme Fluorescent probe, in study of drug binding, 24,458 drug-metabolizing 5-Fluoro-2’-deoxycytidine, effect on DNA metabolism in HeLa cells, effect of aging (rabbit), 23, 244 23, 171 hepatic microsomal (rabbit), 23, 244 2-Fluoroestradiol inactivation, cytochrome P-450 (rat), 23, 445 carcinogemcity (hamster), 23, 278 interaction of full and partial inhibitors, 24, 30 estrogenicity (hamster), 23, 278 kinetics, liver and lung (rat), 24, 300 4-Fluoroestradiol polyamine, alteration (rat), 23, 641 carcinogenicity (hamster), 23, 278 Epinephrine estrogemcity (hamster), 23, 278 effect on epithelial cyclic AMP levels (rat), 23, 228 5-Fluorouracil nonselective beta-adrenergic agonist, binding in heart (human), 24, cellular activity, relationship to folate cofactor pools, 23, 190 169 effect on colon carcinoma cells (human), 23, 540 SUBJECT INDEX 545

5-Fluorouridine, effect on colon carcinoma cells (human), 23, 540 -sensitive sites Fluphenazine, effect on smooth muscle (bovine), 23, 665 binding of [‘H]cis-methyldioxolane in caudate nucleus (porcine), Flunitrazepam, 3H-labeled, binding sites, solubility (rat), 23, 310 24, 374 Folate [3H]cis-methyldioxolane binding to (porcine), 24, 366 antagonists, of tetrahydrobiopterin, 24, 103 cellular cofactor pools, 23, 190 H nitrous oxide (rat), 24, 124 Formate, oxidation (rat), 23, 724 2’-Halogeno-2’-deoxyuridines, interaction with erythrocyte nucleoside Forskolin, effect on sperm adenylate cyclase, 24, 42 transport mechanism (human), 23, 146 Fortimicin, conformation, 23, 127 Halogenonucleosides, interaction with deoxyuridines (human), 23, 146 Free radical, p-aminophenol oxidation, 23, 461 Halothane chronotropic response, 23, 417 effect G on beating in heart cells in culture, 23, 417 Gallamine on secretion of liver proteins (rat), 24, 277 effect on muscarinic receptors (rat), 23, 551 on synthesis of liver proteins (rat), 24, 277 interaction with muscarinic receptors (rat), 23, 551 inotropic response, 23, 417 muscarinic receptor induction (rat), 24, 15 Harmala alkaloid, ionization, 23, 614 neuromuscular blocking (rat), 24, 15 Heart Gastric inhibitory polypeptide, effect on 3-O-methyl-D-glucose in iso- atrium, phosphatidylinositol metabolism (mouse), 24, 351 lated hepatocytes (rat), 23, 141 auricles, beta-adrenergic receptors (human), 24, 169, 174 Gelation beta-adrenergic receptors (rat), 24, 174 hemoglobin 5, 23, 100 cells inhibitors, model class, 23, 100 in culture, effect of calcium on beating, 23, 417 Gene in culture, effect of halothane on beating, 23, 417 coordinated regulation (rat), 23, 779 muscarinic receptors (rat), 24, 15 glucocorticoid-inducible, in hepatoma cells (rat), 23, 779 HeLa cell GH3 cell DNA metabolism, 23, 171 Ca2-dependent cyclic AMP accumulation (rat), 23, 399 53 Ca2 mobilization (rat), 23, 399 nucleus, chromatin, 23, 493 Gland, submaxillary, alpha ,-adrenergic receptor turnover (rat), 23,282 nucleus, effects of auromomycin, 24, 97 Glucagon, effect on 3-O-methyl-D-glucose in isolated hepatocytes (rat), Heme 23, 141 activation of guanylate cyclase (human), 23, 653 Glucocorticoid dependency, guanylate cyclase activation (human), 23, 653 effect on GTP-dependent adenylate cyclase activity, 23, 648 stimulation of cyclic GMP (human), 23, 653 -inducible genes in hepatoma cells (rat), 23, 779 Hemoglobin response variants (rat), 23, 779 covalent binding of 4-dimethylaminophenol (human), 24, 282 Glucose metabolism, sorbital pathway, 24, 521 sickle, solubility, 23, 100 Glutamate receptor, in hippocampus, 24,222,229 Hemoproteins, effect on platelet aggregation (human), 23, 653 Glutathione, bromobenzene metabolism (rat), 23, 235 Hepatocyte, isolated Glycogen 3-O-methyl-D-glucose uptake (rat), 23, 141 hepatocytic (rat), 23, 235 monooxygenase activity (rat), 23, 235 metabolism, cyclic AMP-mediated regulation (Ascaris), 23, 378 Hepatoma cell synthase, muscle, effect of levamisole (Ascaris), 23, 378 variant, glucocorticoid-inducible gene (rat), 23, 779 Gonadotropin-releasing hormone, binding to anterior pituitary (rat), wild-type, glucocorticoid-inducible gene (rat), 23, 779 23,44 Hepatotoxicity, see also Toxicity Growth inhibition, by metals, 24, 77 cocaine (mouse), 23, 482 GTP Herpes simplex virus binding protein, caudate nucleus (porcine), 24, 366, 374 -infected cells, 24,90 -dependent adenylate cyclase activity, 23, 648 mutants, 24, 316 GTPase thymidine kinase, 24, 316 high-affinity thymidylate kinase, 24, 316 effect on adenylate cyclase activity, 24, 380 Heterogeneity in 549 lymphoma cyc and H21a variants, 24, 183 benzodiazepine receptor interactions with ‘y-aminobutyric acid and somatostatin stimulation, 24, 183 barbiturate receptor sites (rat), 23, 315 stimulation, 24, 380 beta-adrenergic receptor binding sites in heart (human), 24, 169, 174 , effects on vas deferens (guinea pig), 23, 409 cardiac muscarinic receptors (rat), 24, 15 Guanine nucleotide(s) nucleoside transport, in mammalian cells, 24, 479 binding, in adrenal membranes (rat), 23, 369 site-site interactions (rat), 24, 357 effect on angiotensin H receptor (rabbit), 24, 213 Hexachlorobiphenyl, metabolism, role of adipose tissue (mouse), 24, regulatory sites, 24, 183 464 synthesis, tiazofurin inhibition, 23, 534 3,4,5,3’,4’,5’-Hexachlorobiphenyl, induction of cytochrome P-448 (rat), Guanoxan, oxidation (human), 23, 474 23, 252 Guanylate cyclase, heme activation (human), 23, 653 Hexachloro-1:3-butadiene Guanyl nucleotide(s) destruction of cytochrome P450-dependent monooxygenases -insensitive sites, binding of [3H]cis-methyldioxolane in caudate flu- (mouse, rat), 23, 206 cleus (porcine), 24, 374 renal necrosis (mouse, rat), 23, 206 regulation of substance P binding in salivary membranes (rat), 23, n-Hexane, metabolism, 2,5-hexanedione, 23, 265 563 Hippocampus salivary gland membrane (rat), 23, 563 acidic amino acid receptors, 24, 222, 229 546 SUBJECT INDEX

Hippocampus-Continued metabolism, pituitary GH3 cells, 24, 189 neurotransmitters, 24, 222 3-O-methyl-D-glucose uptake in isolated hepatocytes (rat), 23, 141 presynaptic receptors, 24, 229 multiple, kinetics, 24, 30 Holoantibiotic, chromophore, 24, 97 NatCa2 exchange in brain (rat), 24, 251 Homogenate, urinary bladder, divalent ion-specific binding of 3H-ATP noncompetitive, drug oxidation (human), 23, 474 (rabbit), 23, 1 nucleoside transport, mecuribenzenesulfonate, 24, 479 Hormone platelet aggregation, by S-nitrosothiols (human), 23, 653 effect on 3-O-methyl-D-glucose uptake in isolated hepatocytes (rat), pregnenolone synthesis, 23, 743 23, 141 product, tyrosine hydroxylase (bovine), 23, 104 gonadotropin-releasing, binding to anterior pituitary (rat), 23, 44 sodium pump, ouabain (bovine), 23, 681 responsiveness, role of cyclic AMP, 23, 384 specific, phosphorylation, 24, 90 steroid, action (rat), 23, 779 summation of effects, 24, 30 Horseradish peroxidase zinc, in hepatic microsomes (rat), 23, 467 benzidine activation, 23, 766 Inhibitor catalysis ofp-aminophenol oxidation, 23, 461 aldose reductase, design, 24, 521 Hydrocarbon, polycyclic aromatic, hepatic metabolism (rat), 24, 115 calmodulin, interaction with calcium channel blockers, 24, 6 Hydrogen, bonding interaction, diphenylhydantoin-9-ethyladenine cholinesterase, structure-activity relationships, 24, 436 complex, 23, 273 dihydrofolate reductase, 24, 103 Hydrogen peroxide endogenous, competition with benzodiazepines in vivo (rat), 23, 310 benzphetamine-induced (rat), 23, 748 full and partial, interaction on single enzyme, 24, 30 formation by hepatic microsomes (rat), 23, 748 methylation, 24, 471 Hydroquinone, formation, in liver (rat), 23, 453 phosphodiesterase, effects on sodium mtroprusside and isoproterenol N-Hydroxyamphetamine, microsomal metabolism (rat), 23, 748 (bovine), 23, 424 Hydroxybenzylpindolol, ‘25I-labeled, binding in heart (human), 24, 169 phospholipase A2, effect on adrenal medullary cells (bovine), 23, 547 Hydroxylation site, aldose reductase, pharmacophor requirements, 24, 521 biphenyl, Km and Vmax (rat), 24, 137 Insulin, effect on 3-O-methyl-D-glucose in isolated hepatocytes (rat), tyrosine, tetrahydrobiopterin as cofactor (bovine), 23, 104 23, 141 4-Hydroxylation, debrisoquine (human), 23, 474 Interaction p-Hydroxylation drug-membrane, 24, 259 aniline, inhibitory activity of alcohols, 23, 213 nonspecific, structural site, 24, 259 microsomal, 23, 213 site-site (rat), 24, 357 Hyperplasia Intestine effect on cyclic AMP-dependent protein kinases (rat), 23, 641 epithelial cells, alpha2-adrenergic receptor (rat), 23, 228 effect on polyamine enzymes (rat), 23, 641 secretion (rat), 23, 228 thyroid, effect on enzymes (rat), 23, 641 Iododeoxyuridine Hypertrophy cytotoxicity, 23, 709 effect on cyclic AMP-dependent protein kinases (rat), 23, 641 metabolism, 23, 709 effect on polyamine enzymes (rat), 23, 641 Ion thyroid, effect on enzymes (rat), 23, 641 divalent Hypophysectomy, effect on thyroid metabolism (rat), 23, 641 3H-ATP binding (rabbit), 23, 1 ATPase activity (rabbit), 23, 1 I flux Ileum adrenal medullary cells (bovine), 23, 671 isolated, muscarimc receptors (guinea pig), 23, 17 in adrenal medullary cells (bovine), 23, 681 substance P, dissociation constant (guinea pig), 23, 558 nickel, effect on [3H]cis-methyldioxolane binding to guanyl nucleo- 2-Imidazolines, identification as anti-sickling agents (human), 23, 731 tide-sensitive sites (porcine), 24, 366 Imipramine, 3H-labeled, binding sites, 23, 607 recognition sites, brain-specific (rat), 23, 326 IMP dehydrogenase, tiazofurmn inhibition, 23, 534 requirements for cellular stimulation (bovine), 23, 671 Inactivation, enzyme, cytochrome P-450 (rat), 23, 445 tetramethylammonium, electron distribution, 24, 443 Induction, drug-metabolizing enzymes (rabbit), 23, 244 Ionization, harmala alkaloids, 23, 614 Inhibition lonophore-receptor complex, group-selective reagent modification, 23, acetylcholine transport (ray), 24, 55 52 adenylate cyclase activity, 24, 380 Iron-complexing agents, 23, 698 adrenal steroidogenesis, 23, 743 Isobutaclamol, conformational properties, 24, 243 brain microtubule assembly, by stypoldione (bovine), 24, 493 Isoenzyme, cytochrome P-450 calcium pump, ouabain (bovine), 23, 681 induction and aging (rabbit), 23, 244 cell division (sea urchin), 24, 500 phenobarbital induction (rat), 23, 265 competitive xylene induction (rat), 23, 265 cholesterol cleavage, 23, 743 Isoproterenol drug oxidation (human), 23, 474 N-alkyl-functionalized carboxylic acid congeners and amides, 24,429 cytochrome P-450, by chloramphenicol (rat), 23, 445 effects on coronary artery cells (bovine), 23, 424 cytochrome P-450, 23, 743 nonselective beta-adrenergic agonist binding in heart (human), 24, gelation, model class, 23, 100 169 growth, by metals, 24, 77 potentiation (bovine), 23, 424 guanine nucleotide, by tiazofurin, 23, 534 Isozyme IMP dehydrogenase, by tiazofurin, 23, 534 cytochrome P-450, 23, 748 kinetics, 23, 717 cytochrome P-450 (rabbit), 24, 156 lymphocyte mitogens, by cyclosporin A, 23, 703 hepatic, cytochrome P-450 (rat), 23, 748 SUBJECT INDEX 547

K metabolism of trans-1,2-dihydroxy-1,2-dihydrobenz[a]anthracene (rat), 24, 115 Kassinin, dissociation constants in ileum (guinea pig), 23, 558 22-Ketocholesterol mixed-function oxidases (rat), 24, 129 oxidation (rat), 23, 467 inhibition of cholesterol cleavage, 23, 743 NADPH phenol metabolism (rat), 23, 453 kinetics of inhibition, 23, 743 monoamine oxidase (human), 24,60 Kidney proteins cytochrome P.450 (mouse, rat), 23, 206 effect of halothane (rat), 24, 277 hexachloro-1:3-butadiene, cytochrome P-450 destruction (mouse, secretion (rat), 24, 277 rat), 23, 206 Location, neutron diffraction, direct determination model, 24, 259 monoamine oxidase (human), 24,60 Kinase , conformational properties, 24, 243 Lung myosin chain, in smooth muscle (bovine), 23, 665 benzo[a]pyrene clearance (rat), 24, 300 myosin light chain, in tracheal smooth muscle, 24, 235 fibroblasts, prostaglandin synthesis (human), 23, 121 protein monoamine oxidase (human), 24, 60 alteration (rat), 23, 641 fl-Lyase, cysteine conjugate (rat), 23, 761 cyclic-AMP-dependent, 24, 235 Lymphoblast thymidine herpes simplex virus, 24, 316 nucleoside kinase-deficient (human), 23, 153 transport, uridine analogues (human), 153 substrate specificity, 24, 316 23, Lymphoblastoid cell, transport of uridine and 6-azauridine (human), thymidylate, herpes simplex virus, 24, 316 23, 153 Kinetics Lymphocyte multiple inhibition, 24, 30 cyclosporin A sensitivity, 23, 703 steady-state, tyrosine hydroxylase (bovine), 23, 104 interaction with metal-complexing compounds, 23, 698 mitogenic stimulation, 23, 698 L mitogens, 23, 703 Lactoperoxidase, benzidine activation, 23, 766 mitogen-stimulated (mouse), 23, 165 Leiurus quinquestriatus, venom neurotoxins, 23, 519 splenic, 2’-deoxycoformycin toxicity (mouse), 23, 165 Leukemia Lymphoid cell line CCRF-CFM cells, drug binding (human), 24,485 inhibition of proliferation, 23, 698 inhibition by 2’-deoxycytidine analogues, 23, 175 interaction with metal-complexing compounds, 23, 698 L1210 cells, inhibition by nucleoside analogues, 23, 175 Lymphoma cell, cyc and H21a variants, 24, 183 Levamisole, effect on muscle contraction and glycogen metabolism M (Ascaris), 23, 378 Ligand Macromolecule, Schistosoma mansoni, drug binding, 24, 291 -receptor binding interactions (bovine), 23, 585 Macrophage, pentoneal, effect of calmodulin on Ca2 uptake (guinea stimulatory, interaction with 2’,S’-dideoxyadenosine, 24, 195 pig), 23, 78 Lipid Magnesium ion, role in adenylate cyclase activation (rat), 23, 369 bilayer, solvation, 24, 259 Malaria, intraerythrocytic, anion transport blockers, 23, 92 vesicles, ionic permeability, 24, 270 Mammary tumor, virus induction (mouse), 23, 779 Lipoprotein, low-density, estrogen action (rat), 24, 69 Marine products, natural (sea urchin), 24, 500 Liver Membrane benzo[a]pyrene clearance (rat), 24, 300 adrenal, guanine nucleotide binding (rat), 23, 369 biphenyl hydroxylation (rat), 24, 137 anterior pituitary, gonadotropin-releasing hormone binding (rat), 23, cysteine conjugate fI-lyase (rat), 23, 761 44 cytochrome P-450 biological forms 2, 4, and 5 (rabbit), 24, 156 effect of electric charge, 24, 270 form 5 (rabbit), 24, 156 interaction with propranolol and timolol, 24, 259 form 5, effect of /1-naphthoflavone (rabbit), 24, 163 cerebellar (rabbit), 24, 23 induction by phenobarbital (rat), 23, 265 -drug interactions, 24, 259 isoenzyme, induction by xylene (rat), 23, 265 erythrocyte, protein, effect of chlorpromazine (human), 23, 771 suicide inactivation (rat), 23, 445 lipidic model, effect of electric charge, 24, 270 daunorubicin-bincling protein (rat), 24, 336 model, interaction with propranolol and timolol, 24, 259 dextromethorphan binding (guinea pig), 23, 629 potential, cerebral cortex (guinea pig), 23, 350 mtDNA polymerase (mouse), 24,329 549 lymphoma cyc and H21a variants, high-affmity GTPase, 24, 183 effect of halothane (rat), 24, 277 salivary gland, substance P binding (rat), 23, 563 estrogen responsiveness (rat), 24, 69 sarcoplasmic reticulum, 24, 259 3-methylcholanthrene treatment (guinea pig), 23, 258 synaptic microsome cholesterol content (mouse), 23, 86 activation of oxidation (rat), 24, 137 striatal, adenylate cyclase activity (rat), 23, 393 benzphetamine oxidation (rat), 23, 748 striatal, muscarinic receptors (rat), 24, 380 biphenyl 2-hydroxylation (rat), 24, 137 synaptosomal, effect of chronic ethanol treatment (mouse), 23, 86 cytochrome P-448 (rat), 23, 252 thalamic (rabbit), 24, 23 cytochrome P450 (guinea pig), 23, 258 transport (human), 23, 146 cytochrome P-450, high-spin form (rat), 24, 146 Mepyramine, 3H-labeled drug-metabolizing enzymes (rabbit), 23, 244 binding to histamine H, receptor, 23, 60 hydrogen peroxide formation (rat), 23, 748 temperature dependence of binding, 23, 60 metabolism of thioacetamide S-oxide (rat), 23, 219 Mercaptan-stimulated DNA scission activity, 23, 500 548 SUBJECT INDEX

Mercuribenzenesulfonate, inhibition of nucleoside transport, 24, 479 binding to guanyl nucleotide-sensitive sites (porcine), 24, 366 Mercury, growth inhibition, 24, 77 Methylene blue, effect in vas deferens (guinea pig), 23, 409 Mercury (II), cell survival after exposure, 24, 84 Methylenedioxybenzene, derivatives, hepatic microsomal (rat), 24, 129 Metabolic clearance rate, methodology, for circulating proteins (rat), 3-O-Methyl-D-glucose, uptake in isolated hepatocytes (rat), 23, 141 23, 112 N-Methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide, action at Metabolism muscarinic cholinergic synapses, 24, 1 adrenal medullary cells (bovine), 23, 671 N-Methyl-4-piperidyl benzilate, binding in adenohypophysis (rat), 24, aromatic amines, in liver (rabbit), 24, 156 357 benzo[a]pyrene, 23, 735 Methyltransferase, thiopurine benzo[a]pyrene (rat), 24, 300 action, 24, 471 product inhibition, 23, 735 effect of benzoic acid derivatives, 24, 471 bromobenzene, glutathione (rat), 23, 235 Metoprolol, binding in heart (human), 24, 169, 174 Ca2, in pituitary tumor cells (rat), 23, 399 Microsome cyclic AMP, muscarinic cholinergic receptor-mediated, 23, 384 benzo[a]pyrene metabolism, 23, 735 drug brain, high-affinity dextromethorphan binding sites (guinea pig), 23, hepatic microsomal enzymes (rabbit), 23, 244 619 reductive (schistosome), 24, 291 hepatic DNA, in HeLa cells, 23, 171 activation of oxidation (rat), 24, 137 glucose, sorbitol pathway, 24, 521 benzphetamine oxidation (rat), 23, 748 glycogen, cyclic AMP-mediated regulation (Ascaris), 23, 378 biphenyl 2-hydroxylation (rat), 24, 137 hexachlorobiphenyl, role of adipose tissue (mouse), 24, 464 cytochrome P-448 (rat), 23, 252 iododeoxyuridine, 23, 709 cytochrome P-450 (guinea pig), 23, 258 microsomal (rat), 24, 300 drug-metabolizing enzymes (rabbit), 23, 244 phenol, hepatic microsome (rat), 23, 453 high-spin form of cytochrome P450 (rat), 24, 146 phosphatidylinositol, in heart (mouse), 24, 351 hydrogen peroxide formation (rat), 23, 748 phosphoinositide, in parotid gland (rat), 23, 71 metabolism of thioacetamide S-oxide (rat), 23, 219 pituitary GH3 cells, 24, 189 metabolism of trans-1,2-dihydroxy-1,2-dihydrobenz[a]anthracene reductive, niridazole (schistosome), 24, 291 (rat), 24, 115 requirements for cellular stimulation (bovine), 23, 671 mixed-function oxidases (rat), 24, 129 stereoselective, polycycic aromatic hydrocarbons (rat), 24, 115 monooxygenase activity (rat), 23, 467 thioacetamide S-oxide (rat), 23, 219 NADPH oxidation (rat), 23, 467 thyroid, effect of hypophysectomy (rat), 23, 641 phenol metabolism (rat), 23, 453 tiazofurin, 23, 534 p-hydroxylation, 23, 213 trans-1,2-dihydroxy-1,2-dihydrobenz[a}anthracene (rat), 24, 115 metabolism (rat), 24, 300 Metabolite, 3-methylcholanthrene (mouse), 23, 198 Microtubule, brain, assembly, inhibition by stypoldione (bovine), 24, Metal 493 complexation, with rifamycins, 23, 133 Microvessel, cerebral -complexing agents, 23, 698 alpha,-adrenergic receptor (dog), 24, 163 -complexing compounds, cellular interaction, 23, 698 phosphatidylinositol effect (dog), 24, 163 essential Mitochondria, hepatic, DNA polymerase (mouse), 24,329 cadmium induction, 24, 77 Mitogen, lymphocyte, 23, 703 growth inhibition, 24, 77 stimulation, 23, 698 non-essential stimulation (mouse), 23, 165 cadmium induction, 24, 77 Mitogenesis, sensitivity to cyclosporin A, 23, 703 growth inhibition, 24, 77 Mitosis, anti-, drugs, 24, 324 Metallithionen, induction by metals, 24, 77 Molecular mass, relative, characteristics, 23, 258 Metamphetamine, microsomal metabolism (rat), 23, 748 Molecular mechanics, calculations, 24, 243 Methanol poisoning (rat), 23, 724 Molecular orbital calculation, electron distribution in tetramethylam- Methionine monium ion, 24, 443 effect on hepatic S-adenosylmethionine (rat), 24, 124 Molecular size, D-dopamine receptor (dog, human), 24, 10 effect on hepatic methylation reactions (rat), 24, 124 Molecular structure, sodium rifamycin SV, 23, 133 nitrous oxide (rat), 24, 124 Molecular topology, steric parameters, 23, 213 synthetase Monoacetylbenzidine, activation by peroxidases, 23, 766 hepatic, effects of methotrexate (rat), 23, 724 Monoamine oxidase hepatic, effects of nitrous oxide (rat), 23, 724 brain (human), 24, 60 Methotrexate, effects on liver (rat), 23, 724 kidney (human), 24, 60 3-Methoxy-4-aminoazobenzene, cytochrome P.450 induction (rat), 24, liver (human), 24, 60 146 lung (human), 24,60 Methylation radioimmunoassay (human), 24,60 nitrous oxide (rat), 24, 124 Monoclonal antibodies, cholinesterases (human), 24, 513 phospholipid, nitrous oxide (rat), 24, 124 Monooxygenase thiol, 24, 471 activity N-Methylcarbazole, N-demethylation, 23, 758 in hepatic microsomes (rat), 23, 467 3-Methylcholanthrene in isolated hepatocytes (rat), 23, 235 effect on hepatocytic monooxygenase activity (rat), 23, 235 betamethasone activation (rat), 24, 137 induction of cytochrome P-448 (rat), 23, 252 cytochrome P-450-dependent, destruction (mouse, rat), 23, 206 induction of cytochrome P450 in fibroblasts (mouse), 23, 198 FAD-containing, N-demethylation of cocaine (mouse), 23,482 cis-Methyldioxolane, 3H-labeled steroid activation (rat), 24, 137 binding in caudate nucleus (porcine), 24, 374 Muscarirnc receptor SUBJECT INDEX 549

acetylcholine, binding in caudate nucleus (porcine), 24, 366 receptor (dog, human), 24, 10 action, 24, 1 semirigid, 24, 243 agonist, inhibition of adenylate cyclase activity (rat), 23, 393 Neuromuscular blocking binding properties (rat), 23, 551 gallamine (rat), 24, 15 cardiac, heterogeneity (rat), 24, 15 pancuronium (rat), 24, 15 effect on phosphatidylinositol metabolism in heart (mouse), 24, 351 Neuron gallamine inhibition (rat), 23, 551 acetylcholine-activated channels, barbiturate effects, 24, 449 heart selectivity (rat), 23, 551 adrenergic, effects of guanethidine (guinea pig), 23, 409 ileal, oxotremorine analogues (guinea pig), 23, 17 serotonergic, association with cocaine binding (mouse, rat), 23, 600 in caudate nucleus (porcine), 24, 366, 374 serotonin uptake, 23,607 modification of binding by gallamine (rat), 23, 551 Neurotoxicity second binding site (rat), 23, 551 esterase (chicken), 23, 717 striate!, coupling to adenylate cyclase, 24, 380 organophosphorus compounds (chicken), 23, 717 Muscle Neurotoxin BC3H-1 clonal cell, 23, 8 polypeptide, 23, 519 contraction, effect of levamisole (Ascaria), 23, 378 scorpion, purification and physiology, 23, 519 L6 cells Neurotransmitter intact, 24, 398 in hippocampus, 24, 222 interactions offull and partial agonists with beta-adrenergic recep- receptor tore, 24, 398 structure (dog, human), 24, 10 levamisole-perfused, cyclic AMP-mediated regulation of glycogen target size (dog, human), 4, 10 metabolism (Ascaris), 23, 378 Neurotumor cell, NCB-20 hybrid, ethylketocyclazocine binding, 23, 486 smooth Neutron diffraction, location, direct determination method, 24, 259 alpha-adrenergic contraction (dog), 23, 570 Nickel contraction (bovine), 23, 665 growth inhibition, 24, 77 contraction (rat), 23, 359 ion, effect on [3H]cis-methyldioxolane binding to guanyl nucleotide- effects of fluphenazine (bovine), 23, 665 sensitive sites (porcine), 24, 366 tracheal, alpha-adrenergic receptors (dog), 23, 570 Nicotinic acetylcholine receptor, effect of semirigid agonists (frog), 23, urinary bladder (rabbit), 23, 1 337 Mutagenesis Niridazole 2-aminoanthracine (rabbit), 24, 156 antiparasitic activity (schistosome), 24, 291 2-aminofluorine (rabbit), 24, 156 reductive metabolism (schistosome), 24, 291 aromatic amine-induced (rabbit), 24, 156 Nitrobenzylthioinosine, effect on nucleoside transport in cultured mam- phenobarbital induction (rabbit), 24, 156 malian cells, 24, 479 Mutant, herpes simplex virus, 24, 316 Nitrogen Myocardium, cell membrane, calcium uptake and release, 23, 417 oxide, effect on platelet aggregation (human), 23, 653 Myosin -steroid mustard, cytotoxicity, 24, 324 light chain kinase Nitroreductase, schistosome, 24, 291 in smooth muscle (bovine), 23, 665 Nitroreduction (schistosome), 24, 291 in tracheal smooth muscle, 24, 235 Nitrothiazole derivative, 24, 291 phosphorylation 2-Nitroso-1-phenylpropane, microsomal metabolism (rat), 23, 748 in smooth muscle (bovine), 23, 665 S-Nitrosothiols, inhibition of platelet aggregation (human), 23, 653 in tracheal smooth muscle, 24,235 Nitrous oxide Myocardium, ventricular receptor for angiotensin II (rabbit), 24, 213 effect on hepatic S-adenosylmethionine (rat), 24, 124 effect on hepatic methylation reactions (rat), 24, 124 effects on liver (rat), 23, 724 N folates (rat), 24, 124 toxicity (rat), 24, 124 2’Na, permeability, carbamylcholine-stimulated, 23,8 Norbenzphetamine, microsomal metabolism (rat), 23, 748 Na Norcocaine, cocaine N-demethylation (mouse), 23, 482 -Ca2, exchange in brain (rat), 24, 251 Norepinephrine, effect on vas deferens (rat), 23, 359 transport in brain (rat), 24, 251 Noscapine, effect on dextromethorphan binding, 23,629 NAD, analogue formation, 23, 534 Nuclear matrix, estramustine binding, 24, 324 NADPH oxidation, effect of zinc (rat), 23, 467 Nuclear Overhauser enhancement, conformation of fortimicins, 23, 127 Naloxone, dynorphin antagonism, 23, 36 Nucleic acid, in colon carcinoma cells in culture (human), 24, 309 ,6-Naphthoflavone, effect on hepatic cytochrome P-450, form 5 (rabbit), Nucleoside 24, 156 erythrocyte transport mechanism, interaction with 2’-halogeno-2’- Naphthoic acid, moiety, 23, 500 deoxyuridines (human), 23, 146 Neocarzinostatin kinase-deficient lymphoblasts (human), 23, 153 circular dichroism, 23, 500 transport (human), 23, 146 chromophore, binding to DNA, 23, 500 heterogeneity in mammalian cells, 24, 479 degradation of chromatin, 23, 493 in cultured mammalian cells, 24, 479 effects on chromatin in HeLa S nuclei, 23, 493 Nucleosome, degradation, 24, 97 fluorescence, 23, 500 Nucleotide Neuroblastoma, delta-subtype opiate receptors, 24, 413 degradation, agonist-induced changes, 23, 384 Neuroblastoma cell, x glioma NG1O8-15 hybrid, opiate regulation of guanine cyclic AMP levels, 23, 26 effect on angiotensin II receptor (rabbit), 24, 213 Neuroleptic regulatory sites, 24, 183 conformational properties, 24, 243 tiazofurin inhibition, 23, 534 550 SUBJECT INDEX

Nucleotide-Continued Percoll density gradient, separation of parenchymal cells (rat), 23, 235 guanyl Permeability, carbamylcholine-stimulated, 23,8 regulation of substance P binding in salivary membranes (rat), 23, Peroxidase 563 benzidine activation, 23, 766 salivary gland membrane (rat), 23, 563 horseradish, benzidine activation, 23, 766 regulatory protein (rat), 24, 341 lactoperoxidase, benzidine activation, 23, 766 sensitivity for beta-adrenergic receptors (rat), 24, 341 pH-dependent transport, in lymphoblastoid cells (human), 23, 153 synthesis, agonist-induced changes, 23, 384 Pharmacokinetics, liver and lung (rat), 24, 300 Nucleus Pharmacology, light-flash (eel), 23, 344 HeLa S cell Pharmacophor requirements of aldose reductase inhibitor site, 24, 521 chromatin, 23, 493 Phencycidine, inhibition of ethylketocyclazocine binding, 23, 486 effects of auromomycin, 24, 97 Phenformin, oxidation (human), 23, 474 soluble chromatin, 24, 97 Phenobarbital effect of long-term administration on hepatic mtDNA polymerase 0 (mouse), 24, 329 Octoclothepin, conformational properties, 24, 243 effect on benzphetamine oxidation (rat), 23, 748 Opiate effect on hepatic aromatic amines (rabbit), 24, 156 multiple binding sites in central nervous system (rabbit), 24, 23 effect on hepatic cytochrome P-450 forms (rabbit), 24, 156 receptor effect on hepatic microsomes (rat), 23, 748 delta-subtype, in neuroblastomas, 24, 413 effect on hepatocytic monooxygenase activity (rat), 23, 235 desensitization in neuroblastoma x glioma NG1O8-15 hybrid cells, hepatic centrilobular hypertrophy after long-term treatment 24, 413 (mouse), 24, 329 down-regulation in neuroblastoma x glioma NG1O8-15 hybrid cells, induction of cytochrome P-450 isozyme (rat), 23, 265 24, 413 mutagenesis induction (rabbit), 24, 156 in neuroblastoma x glioma NG1O8-15 hybrid cells, 23, 26 Phenol, biotransformation, by liver microsomes (rat), 23, 453 mu and kappa subtypes from brain (rat), 24, 203 Phenothiazine, effect on dextromethorphan binding, 23, 629 regulation, cellular cyclic AMP, 23, 26 Phenylalanine derivatives, effect on deoxyhemoglobin 5, 23, 100 receptor, kappa, 23, 36 Phenyl N-methyl carbamates, affinities, quantum mechanical study, Organophosphorus compounds, neurotoxicity (chicken), 23, 717 24, 436 Ornithine decarboxylase, thyroid (rat), 23, 641 2-(4-Phenylpiperidino)cyclohexanol, effect on acetylcholine transport Ouabain (ray), 24, 48 calcium pump inhibition (bovine), 23, 681 Phorbol esters, tumor-promoting, 23, 703 effect on adrenal medullary cells (bovine), 23, 681 Phosphatidic acid, synthesis in parotid gland (rat), 23, 71 sodium pump inhibition (bovine), 23,681 Phosphatidylinositol -stimulated secretion in adrenal medullary cells (bovine), 23, 671 effect in cerebral microvessels (dog), 24, 163 Oxidase, mixed-function, microsomal (rat), 24, 129 metabolism in heart (mouse), 24, 351 Oxidation Phosphodiesterase inhibitors p-aminophenol, catalysis, 23, 461 effects on coronary artery cells (bovine), 23, 424 formate (rat), 23, 724 effects on sodium nitroprusside and isoproterenol (bovine), 23, 424 NADPH Phosphoinositide effect of zinc (rat), 23, 467 metabolism in heart (mouse), 24, 351 in hepatic microsomes (rat), 23, 467 metabolism in parotid gland (rat), 23, 71 sequential, benzphetamine (rat), 23, 748 Phospholipase A2 inhibitors, effect on adrenal medullary cells (bovine), N-Oxidation 23, 547 cytochrome P-450 (mouse), 23, 482 Phospholipid, methylation, nitrous oxide (rat), 24, 124 FAD-containing monooxygenase (mouse), 23, 482 Phosphorylase Oxotremorine analogue(s), 24, 1 muscle, effect of levamisole (Ascaris), 23, 378 ileal muscarmnic receptors (guinea pig), 23, 17 smooth muscle (bovine), 23, 665 Oxygen atom, source in N-demethylation reactions, 23, 758 Phosphorylation Oxygen 18 incorporation (rat), 23, 219 myosin in smooth muscle (bovine), 23, 665 P in tracheal smooth muscle, 24, 235 Pancreozymin, effect on 3-O-methyl-D-glucose in isolated hepatocytes 5-trifluoromethyl-2 ‘-deoxyuridine, 24, 90 (rat), 23, 141 Physalaemin, dissociation constants in ileum (guinea pig), 23, 558 Pancuronium Physical dependence, ethanol (mouse), 23, 86 muscarinic receptor induction (rat), 24, 15 Physical state, lipid bilayer properties, drug solvation, 24, 259 neuromuscular blocking (rat), 24, 15 Physiology, scorpion neurotoxins, 23, 519 Paralysis, role ofcycic AMP-mediated glycogen metabolism (Ascaris), Picrotoxin receptor, brain-specific binding (rat), 23, 326 23, 378 Picrotoxinin receptor, computer-assisted modeling, 23, 511 Parasite, Schistosoma mansoni, macromolecular drug binding, 24, 291 Pindolol, binding in heart (human), 24, 169 Parotid gland Pituitary calcium mobilization (rat), 23, 71 anterior phosphatidic acid synthesis (rat), 23, 71 adenylate cyclase (rat), 23, 576 phosphoinositide metabolism (rat), 23, 71 D-2 dopamine receptor (bovine), 23, 585 Peptide, vasoactive intestinal D2 dopamine receptor (rat), 23, 576 epithelial (rat), 23, 228 gonadotropin-releasing hormone binding (rat), 23, 44 modulation of adenylate cyclase in pituitary GH3 cells, 24, 189 intact cells (bovine), 23, 295 modulation of cyclic AMP content in pituitary GH3 cells, 24, 189 GH3 cells modulation of prolactin secretion in pituitary GH3 cells, 24, 189 adenylate cyclase, 24, 189 SUBJECT INDEX 551

cyclic AMP content, 24, 189 liver, effect of halothane (rat), 24, 277 prolactin secretion, 24, 189 nucleotide regulatory (rat), 24, 341 neurointermediate lobe, [3HJprazosin-labeled alphai-receptors (por- secretion, effect of halothane (rat), 24, 277 cine), 24, 409 synthesis, in colon carcinoma cells in culture (human), 24, 309 tumor cells Ca2-dependent cyclic AMP accumulation (tat), 23, 399 Ca2 metabolism (rat), 23, 399 Q pKa, low, anomalous, 24, 243 Quantum mechanics, in study of phenyl N-methyl carbamates, 24, 436 Plasma, butyrylcholinesterase, monoclonal antibodies (human), 24, 513 Quinazolines, conformation for binding, 24, 425 Plasmodium fakiparum, growth suppression in vitro, 23,92 Quinine, effect in vas deferens (guinea pig), 23, 409 Platelet Quinone, intercalation, DNA, 23, 735 aggregation, inhibition by S-nitrosothiols (human), 23, 653 Quinuclidinyl benzilate, binding in adenohypophysis (rat), 24, 357 cocaine binding (human), 23, 600 serotonin uptake, 23,607 Poisoning, methanol (rat), 23, 724 R Polyamine, enzyme alteration (rat), 23, 641 Polychlorinated biphenyl Radiation inactivation, in study of dopamine D2 receptor (dog, human), induction of high-spin form of cytochrome P450 (rat), 24, 146 24, 10 pharmacokinetics, induction of drug-metabolizing enzymes (mouse), Radical, free, in benzidine oxidation, 23, 766 24,464 Radioligand, binding in trachea (dog), 23, 570 Polycycic aromatic hydrocarbon, hepatic metabolism (rat), 24, 115 Radioimmunoassay Polymerase, mtDNA, characterization (mouse), 24, 329 double-antibody, identification of hepatic cytochrome P-448, 23, 252 Polymorphism, drug oxidation (human), 23, 474 monoamine oxidase (human), 24, 60 Polyol, pathway, 24, 521 Receptor Polypeptide, neurotoxins, 23, 519 acetylcholine Potassium, calcium-activated conductance (guinea pig), 23, 409 effect of cis-bis-Q (eel), 23, 344 Potentiation nicotinic, agonist occupation and functional response, 23, 8 isoproterenol effects (bovine), 23, 424 adenohypophyseal, effect of muscarinic antagonists on conformation sodium nitroprusside effects (bovine), 23, 424 (rat), 24, 357 P Site, stimulatory ligands, 24, 195 adrenergic, see Adrenergic receptor Purification -agonist, high-affinity states (bovine), 23, 295 duanorubicin-binding protein from liver (rat), 24, 336 amino acid, acidic, in hippocampus, 24, 222, 229 scorpion neurotoxins, 23, 519 y-aminobutyric acid Pyrazolopyridines, brain-specific binding (rat), 23, 326 -chloride ion channel complex (rat), 23, 315 Practolol binding in heart (human), 24, 169, 174 interactions with benzodiazepine receptor (rat), 23, 315 Prazosin, 3H-labeled, alpha,-receptors in pituitary (porcine), 24, 409 barbiturate, interactions wiht benzodiazepine receptor (rat), 23, 315 Pregnenolone synthesis, inhibition, 23, 743 benzodiazepine Procaterol, binding in heart (human), 24, 169, 174 binding, extraction in distilled water (rat), 23, 310 Products, natural, marine (sea urchin), 24, 500 binding kinetics (rat), 23, 289 Prolactin brain-specific (rat), 23, 326 effect on Ca2 metabolism in pituitary tumor cells (rat), 23, 399 conformational change (rat), 23, 289 effect on cyclic AMP accumulation in pituitary tumor cells (rat), 23, endogenous inhibitor(s), (rat), 23, 310 399 interactions with y-aminobutyric acid and barbiturate receptor -modulating hormones, effect on Ca2 and cyclic AMP (rat), 23, 399 sites (rat), 23, 315 regulation (rat), 23, 576 ligand interactions, 24, 425 secretion in pituitary GH3 cells, 24, 189 subtypes (rat), 23, 315 Propranolol brain antidepressants, 23, 594 binding in heart (human), 24, 169, 174 y-butyrolactone, computer-assisted modeling, 23, 511 interaction with membranes, 24, 259 complexes in brain (rat), 23, 326 Propylthiouracil divalent cation, salivary gland membrane (rat), 23, 563 -stimulated thyroid hyperplasia (rat), 23, 641 dopamine -stimulated thyroid hypertrophy (rat), 23, 641 adenohypophyseal (rat), 23, 576 Prostaglandin agonist/antagonist interactions (rat), 23, 303 E,, intestinal epithelial (rat), 23, 228 binding on intact cells (bovine), 23, 295 synthase, catalysis ofp-aminophenol oxidation, 23, 461 D2 (bovine), 23, 585 synthesis, effect of cannabinoids (human), 23, 121 D2, characterization (rat), 23, 576 Protein D2, molecular size (dog, human), 24, 10 antitumor in brain (dog, human), 24, 10 antibiotic, 23, 500 molecular weight (dog, human), 24, 10 effect on HeLa S3 nuclei, 24, 97 thermodynamics (rat), 23, 303 carboxymethylation, nitrous oxide (rat), 24, 124 dynorphin circulating, metabolic clearance rate (rat), 23, 112 ileum (guinea pig), 23, 36 covalent binding (rat), 23, 219 vas deferens (mouse), 23, 36 daunorubicin-binding, from liver (rat), 24, 336 estrogen, hepatic (rat), 24, 69 erythrocyte membrane, effect of chlorpromazine (human), 23, 771 glutamate, in hippocampus, 24, 222, 229

estrogen-binding (rat), 24, 69 histamine H, , [3H]mepyramine binding, 23,60 kinase -ionophore complex, group-selective reagent modification, 23, 52 alteration (rat), 23, 641 -ligand binding interactions (bovine), 23, 585 cyclic AMP-dependent, 24, 235 low-affinity states, 24, 398 552 SUBJECT INDEX

Receptor-Continued Resistance multiple binding states (bovine), 23, 585 drug, mechanism (human), 24, 485 multiple opiate, 23, 486 vinblastine (human), 24, 485 multiplicity, binding in brain (rat), 23, 326 Vinca alkaloid (human), 24,485 muscarinic Reticulocyte, beta-adrenergic receptors (rat), 24, 174 acetylcholine, binding in caudate nucleus (porcine), 24, 366 Reticulum, sarcoplasmic, membrane, 24, 259 action, 24, 1 2-$-D-Ribofuranosylthiazole-4-carboxamide, metabolism, 23, 534 adenohypophyseal (rat), 24, 357 Ribonucleoside, triphosphates, lymphocytic (mouse), 23, 165 agonist, inhibition of adenylate cyclase activity (rat), 23, 393 Rifamycin SV, sodium salt, molecular structure, 23, 133 binding properties (rat), 23, 551 RNA cardiac, heterogeneity (rat), 24, 15 messenger cholinergic, effect on cyclic AMP metabolism, 23, 384 in vitro translation (human), 23, 540 coupling to adenylate cyclase, 24, 380 in vitro translational activity, 24, 509 effect on phosphatidylinositol metabolism in heart (mouse), 24, polyadenylated, sangivamycin incorporation (human), 24, 509 351 synthesis, in lymphocytes (mouse), 23, 165 gallamine inhibition (rat), 23, 551 Ro 11-2465 binding, 23, 607 heart selectivity (rat), 23, 551

ileal, oxotremorine analogues (guinea pig), 23, 17 S in caudate nucleus (porcine), 24, 366, 374 modification of binding by gallamine (rat), 23, 551 Salbutamol, binding in heart (human), 24, 169, 174 second binding site (rat), 23, 551 Salivary gland, membranes, substance P binding (rat), 23, 563 neuroleptic (dog, human), 24, 10 Sangivamycin neurotransmitter effect on messenger RNA (human), 24, 509 structure (dog, human), 24, 10 treatment of colon carcinoma cells (human), 24, 509 target size (dog, human), 24, 10 Saponin, macrophage treatment (guinea pig), 23, 78 nicotinic Sarcoplasmic reticulum, membrane, 24, 259 acetylcholine, effect of semirigid agonists (frog), 23, 337 Schistosoma mansoni, reductive metabolism of niridazole, 24, 291 cholinergic, in brain (rat), 24, 387 Schistosome, nitroreductase, 24, 291 chromaffin cell (bovine), 23, 437 Scorpion venom occupancy in vas deferens (rat), 23, 359 binding in cerebral cortex (guinea pig), 23, 350 opiate neurotoxins, 23, 519 delta-subtype, in neuroblastomas, 24, 413 Secretion desensitization in neuroblastoma X glioma NG1O8-15 hybrid cells, ascorbic acid, chromaffin cells (bovine), 23, 437 24, 413 calcium uptake (bovine), 23, 547 down-regulation in neuroblastoma x glioma NG1O8-15 hybrid cells, catecholamine, adrenal medullary cells (bovine), 23, 547, 671, 681 24, 413 liver proteins, effect of halothane (rat), 24, 277 in neuroblastoma x glioma NG1O8-15 hybrid cells, 23, 26 Seminal vesicle, microsomes, p-aminophenol oxidation, 23, 461 mu and kappa subtypes from brain (rat), 24, 203 Sensitivity opioid, kappa, 23, 36 drug, modified, herpes simplex virus, 24, 316 picrotoxin, brain-specific binding (rat), 23, 326 nucleotide, for beta-adrenergic receptors (rat), 24, 341 picrotoxinin, computer-assisted modeling, 23, 511 Serotonin presynaptic, in hippocampus, 24, 229 binding (mouse, rat), 23, 600 serotonin, antagonist, 23, 594 uptake spare neuronal, 23, 607 dynorphin potency, 23, 36 platelet, 23, 607 ileal (guinea pig), 23, 17 receptor, antagonist, 23, 594

substance P Serotonin, , binding sites, 23, 594 in ileum (guinea pig), 23, 558 Sickle cell anemia, 2-imidazoline treatment (human), 23, 731 in salivary membranes (rat), 23, 563 Sex differences, translocation receptors (rat), 24, 69 inactivation with phenoxybenzamine (guinea pig), 23, 558 Sex differentiation, estrogen-binding proteins (rat), 24, 69 2,3,7,8-tetrachlorodibenzo-p-dioxin in fibroblasts (mouse), 23, 198 Sodium translocation, in sex differentiation (rat), 24, 69 channel ventricular myocardial, for angiotensin II (rabbit), 24, 213 cerebral cortex (guinea pig), 23, 350 Reconstitution, ion exchange, in brain (rat), 24, 251 effect of scorpion neurotoxins, 23, 519 Reductase, aldose efflux assay, acidic amino acid receptors in hippocampus, 24, 222 inhibitor site, pharmacophor requirements, 24, 521 pump, inhibition by ouabain (bovine), 23, 681 inhibitors, design, 24, 521 Sodium nitroprusside Regulation effects on coronary artery cells (bovine), 23, 424 Ca2-dependent cyclic AMP accumulation in pituitary tumor cells potentiation (bovine), 23, 424 (rat), 23, 399 Solubility cellular cyclic AMP, by opiates, 23, 26 deoxyhemoglobin 5, 23, 100 genetic, coordinated (rat), 23, 779 [3H]flunitrazepam binding sites, effect of diazepam (rat), 23, 310 prolactin (rat), 23, 576 Solubilization Regulator benzodiazepine binding sites, with distilled water (rat), 23, 310 deoxycytidylate deaminase, chemotherapeutic implications (human), mu and kappa opiate receptor subtypes from brain (rat), 24, 203 23, 159 Solvation enzymic, action (human), 23, 159 enzyme inhibition, nonspecific site of interaction, 24, 259 Relative molecular mass, characteristics, spectrum, 23, 258 lipid bilayer, 24, 259 Relaxation, beta-adrenergic, in tracheal smooth muscle, 24, 235 Somatostatin SUBJECT INDEX 553

adenylate cyclase inhibition, 24, 183 23, 159 GTPase stimulation, 24, 183 specificity (human), 23, 159 -induced stimulation of GTPase, 24, 183 4-hydroxylation of debrisoquine (human), 23, 474 Sorbitol pathway, glucose metabolism, 24, 521 thymidine kinase, 24, 316 Sparteine, oxidation (human), 23, 474 Supersensitivity, acid amino acid receptors in hippocampus, 24, 229 Specificity, substrate (human), 23, 159 Synapse, muscarinic cholinergic, 24, 1 4-hydroxylation of debrisoquine (human), 23, 474 Synaptic membrane, striatal Spectral property, neocarzinostatin chromophore, 23, 500 adenylate cyclase activity (rat), 23, 393 Sperm, adenylate cyclase, effect of forskolin, 24, 42 muscarinic receptors (rat), 24, 380 Spin label, in study of ethanol tolerance (mouse), 23, 86 Synaptic vesicle Spiroperidol, 3H-labeled acetylcholine transport (ray), 24, 48 binding on intact cells (bovine), 23, 295 cholinergic (ray), 24, 48, 55 in striatum (rat), 23, 303 Synaptosomal vesicles, in brain (rat), 24, 251 temperature dependency (rat), 23, 303 Synergism, summation of inhibitory effects, 24, 30 Spleen, lymphocytes, 2 ‘-deoxycoformycin toxicity (mouse), 23, 165 Synthesis Splenocyte, interaction of metal-complexing compounds, 23, 698 DNA, inhibition, 23, 698 Stereoselectivity, oxotremorine analogues, for ileal muscarinic recep- liver proteins, effect of halothane (rat), 24, 277 tom (guinea pig), 23, 17 prostaglandin, effect of cannabinoids (human), 23, 121 Stereospecificity, gelation inhibitors, 23, 100 Steroid T activation of monooxygenases (rat), 24, 137 glucocorticoid, effect on cultured fibroblasts, 23, 648 Target size, neurotransmitter receptors (dog, human), 24, 10 hormone, action (rat), 23, 779 Temperature -nitrogen mustard, cytotoxicity, 24, 324 dependence Steroidogenesis, adrenal, inhibition, 23, 743 agonist binding, 24, 392 Stimulation [3H}mepyramine binding, 23,60 ionic, cellular (bovine), 23, 671 effect on dextromethorphan binding (guinea pig), 23, 619 metabolic, cellular (bovine), 23, 671 effect on [3H]spiroperidol binding (rat), 23, 303 metabolism, pituitary GH3 cells, 24, 189 Testis, adenylate cyclase, effect of forskolin, 24, 42 muscarirnc, cyclic GMP, 24, 1 Tetrabenazine, binding, chromaffin granules (bovine), 23, 431 somatostatin-induced, GTPase, 24, 183 2,3,7,8-Tetrachlorodibenzo-p-dioxin, receptor in fibroblasts (mouse), Striatum 23, 198 dopamine receptor binding (rat), 23, 303 Tetrahydrobiopterin muscarinic receptors, coupling to adenylate cyclase, 24, 380 biosynthesis, 24, 103 synaptic membranes folate antagonists, 24, 103 adenylate cyclase activity (rat), 23, 393 Tetrahydrofolate, hepatic, regulation (rat), 23, 724 muscarinic receptors (rat), 24, 380 Tetrahydropterin, cofactor in tyrosine hydroxylation (bovine), 23, 104 Structure Tetrahydrotrazodone neocarzinostatin chromophore, 23, 500 binding sites, 23, 594 requirements for drug binding on human serum albumin, 24,458 3H-labeled, binding, 23, 594 Structure-activity relationship Tetramethylammonium ion, electron distribution, 24, 443 ansamycins, 23, 133 Tetraphenylborate, effect on acetylcholine transport (ray), 24, 55 cholinesterase inhibitors, 24, 436 Thalamus 3-dimensional, in aminoglycoside antibiotics, 23, 127 kappa opiate agonists (rabbit), 24, 23 human serum albumin site II, 24,458 membranes (rabbit), 24, 23 in interactions ofalkoxymethylenedioxybenzene derivatives (rat), 24, Thioacetamide S-oxide, metabolism (rat), 23, 219 129 Thiol induction (rat), 24, 129 methylation, 24, 471 oxotremorine analogues, 23, 17 nonprotein depletion (schistosome), 24, 291 quantitative Thiopurine methyltransferase enzyme inhibition, 23, 213 action, 24, 471 study, inhibition of microsomal p-hydroxylation, 23, 213 effect of benzoic acid derivatives, 24, 471 Stypoldione Thymidine kinase effect on embryonic cell cycle progression (sea urchin), 24, 500 effects of 5’-amino-5’deoxythymidine, 23, 709 effect on embryonic cell division (sea urchin), 24, 500 herpes simplex virus, 24, 316 effect on embryonic DNA and protein synthesis (sea urchin), 24, 500 preferential inhibition, 24, 90 inhibition of brain microtubule assembly (bovine), 24, 493 substrate specificity, 24, 316 Submaxillary gland, alpha,-adrenergic receptor turnover (rat), 23, 282 Thyrnidylate kinase Substance P effects of 5’-amino-5’-deoxythymidine, 23, 709 analogues, dissociation constants (guinea pig), 23, 558 herpes simplex virus, 24, 316 binding to salivary membranes (rat), 23, 563 Thyroid dissociation constant (guinea pig), 23, 558 hyperplasia in ileum (guinea pig), 23, 558 effect on enzymes (rat), 23, 641 receptor propylthiouracil-stimulated (rat), 23, 641 dissociation constants in ileum (guinea pig), 23, 558 hypertrophy in salivary membranes (rat), 23, 563 effect on enzymes (rat), 23, 641 inactivation with phenoxybenzamine (guinea pig), 23, 558 propylthiouracil-stimulated (rat), 23, 641 Substrate metabolism, effect of hypophysectomy (rat), 23,641 deoxycytidylate deaminase, chemotherapeutic implications (human), ornithine decarboxylase (rat), 23, 641 554 SUBJECT INDEX

Thyrotropin-releasing hormone, in GH3 cells, effect on Ca2 and cyclic U AMP (rat), 23, 399 Uptake, 3-O-niethyl-D-glucose, in isolated hepatocytes (rat), 23, 141 Tiazofurin, see 2-/1-D-Ribofuranosylthiazole-4-carboxamide Uridine Timolol, interaction with membranes, 24, 259 analogues Tolbutamide, oxidation (human), 23, 474 transport in lymphoblastoid cells (human), 23, 153 Tolerance, ethanol, synaptosomal plasma membranes (mouse), 23,86 transport in lymphoblastoid cells (human), 23, 153 Torpedo californica, electric organ, acetylcholine transport, 24, 48, 55 Toxicity, see also Cytotoxicity, Hepatotoxicity cytological, a-1,3,5-triglycidyl-s-triazinetrione, 23, 182 V 2’-deoxycoformycin, in spleen lymphocytes (mouse), 23, 165 Vas deferens hepatic, cocaine (mouse), 23, 482 alpha,-adrenergic receptors (rat), 23, 359 nitrous oxide (rat), 24, 124 contraction (rat), 23, 359 Toxin effects of apamine, methylene blue, and quinine (guinea pig), 23,409 cholera, effect on GTPase activity in striatal membranes (rat), 24, effects of guanethidine (guinea pig), 23, 409 380 Vasoactive intestinal peptide cobra a-, ‘9-labeled, 23, 8 epithelial cell (rat), 23, 228 Trachea, smooth muscle (bovine), 23, 665 modulation of adenylate cyclase in pituitary GH3 cells, 24, 189 alpha-adrenergic receptors (dog), 23, 570 modulation of cyclic AMP in pituitary Gil, cells, 24, 189 contraction (dog), 23, 570 modulation of prolactin secretion in pituitary GH3 cells, 23, 189 myosin phosphorylation, 24, 235 Venom, scorpion, neurotoxins, 23, 519 Translation in vitro, messenger RNA (human), 23, 540; 24, 509 Ventricle, myocardial receptor for angiotensin II (rabbit), 24, 213 Transport Vesicle acetylcholine lipid, ionic permeability, 24, 270 effect of tetraphenylborate (ray), 24, 55 synaptosomal, in brain (rat), 24, 251 in synaptic vesicles (ray), 24, 48 Vinblastine, cellular accumulation (human), 24, 485 anion Vinca alkaloid inhibition (ray), 24, 55 cellular accumulation (human), 24, 485 inhibitors, 23, 92 retention, energy-dependent (human), 24, 485 axonal, beta-adrenergic receptors (rat), 24, 341 Virus, mammary tumor induction (mouse), 23, 779 6-azauridine, in lymphoblastoid cells (human), 23, 153 Voltage-sensitive channel, cerebral cortex (guinea pig), 23, 350 Ca2, in brain (rat), 24, 251 electron, enhanced (rat), 24, 137 W membrane (human), 23, 146 Na, in brain (rat), 24, 251 Water, solubiity of [3H]flunitrazepam binding sites (rat), 23, 310 nucleoside (human), 23, 146 heterogeneity in mammalian cells, 24, 479 x in lymphoblastoid cells (human), 23, 153 mercuribenzenesulfonate inhibition, 24, 479 Xanthines, effect on coronary artery cells (bovine), 23, 424 pH-dependent, in lymphoblastoid cells (human), 23, 153 X-ray uridine, in lymphoblastoid cells (human), 23, 153 cell survival after exposure, 24,84 Tremorolytic agents, stereoselectivity (guinea pig), 23, 17 crystallography, conformation of neuroleptics, 24, 243 Trifluoperazine, antagonism, alpha,-adrenergic effects, 23, 67 Xylene, induction of cytochrome P-450 isozyme (rat), 23, 265 5-Trifluoromethyl-2 ‘-deoxyuridine, phosphorylation, preferential inhi- bition, 24, 90 Y a-1,3,5-Triglycidyl-s-triazinetrione, antitumor and cytotoxic effects, 23, 182 Yeast, growth inhibition, by aromatic heptaene macrolide antibiotics, Triphenylmethylphosphonium, effect on binding and depolarization in 24, 270 cerebral cortex (guinea pig), 23, 350 Yohimbine, 3H-labeled Tumor binding (rat), 23, 228 mammary, virus induction (mouse), 23, 779 identification of alpha2-adrenergic receptor (rat), 23, 228 pituitary cellular Ca2 metabolism (rat), 23, 399 z cellular cyclic AMP accumulation (rat), 23, 399 -promoting phorbol esters, 23, 703 Zinc Turnover, alpha,-adrenergic receptor in submaxillary gland (rat), 23, effect on monooxygenase activity (rat), 23, 467 282 effect on NADPH oxidation (rat), 23, 467 Tyrosine hydroxylase growth inhibition, 24, 77 dead-end and product inhibition (bovine), 23, 104 inhibition, in hepatic microsomes (rat), 23, 467 steady-state kinetics (bovine), 23, 104 Zinterol, binding in heart (human), 24, 169, 174 U.S. POSTAL URVICE STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION (R.qulrid by 39 U.S.C. 3685)

1. TITLE OF PUBLICATION A. PUBLICATION NO. J 2. DATE OF FILING t1ecu1ar Pharmacology 3 I I8 6 f5 0 0 0 10/1/83 3. FREQUENCY OF ISSUE A. NO. OF ISSUES PUBLISHED I a. ANNUAL. SUBSCRIPTION ANNUALLY PRICE

Bi-uonthly . 6 rnstitutiona1:$140.

4. COMPLETE MAIUNG ADDRESS OF KNOWN OFFiCE OF PUBLICATION (Strs., City, County, St.S#{149}and ZIP Cod.) (Not prlnt.rs)

9650 Rockville Pike, Bethesda, Maryland 20814

5 COMPLETE MAIUNG ADDRESS OF THE HEADQUARTERS OR GENERAL. BUSINESS OFFICES OF THE PUBLISHERS (Not prlntws)

9650 Roekville Pike, Bethesda, Maryland 20814

t FULL NAMES AND COMPLETE MAILING ADDRESS OF PUBLISHER, EDITOR, AND MANAGING EDITOR (The Itn MUST NOT b. blank)

PUBLISHER (Nsms and Complst#{149} MaflIng Addr.sa) The Mrican Society for Pharmacology 9650 Rockville Pike and Experinnta1 Therapeutics Beda, Maryland 20814 EDITOR (Nsm nd Compl.t. Mailing Addrsss) Dr. Joel C. Hardman Vanderbilt University Schol of ldicine

of Pharmacology Nashville, Tennessee 37232 MANAUINU EDITOR (Nam. and CompS#{149} MaIlIng Addrsss) Kay A. Croker, Executive Officer 9650 Rockville Pike Amnnricari Society for Pharmacology & Experirrnta1 Therapeutics Bethesda, Maryland 20814

7. OWNER (If owned by a corporation. its name and address must be stated and also immediately thereunder the names and addresses of stockholders owning or holding 7 percent or more of total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must be given. If owned by a partnership or other unincorporated firm, its name and address, as well as that of each individual must be given. If the publica- tion is published by a nonprofit organization, its name and address must be stated.) (Item must be completed)

FULL NAME COMPLETE MAILING ADDRESS Aurican Society for Pharmacology 9650 Rockville Pike and Experiuntal Therapeutics B#{233}th#{233}sd#{225}. t’r’d&id 20814

8. KNOWN BONDHOLDERS. MORTGAGEES. AND OTHER SECURITY HOLDERS OWNING OR HOLDING 1 PERCENT OR MORE OF TOTAL AMOUNT OF BONDS. MORTGAGES OR OTHER SECURITIES (II th, ars non., so state)

FULL NAME COMPLETE MAILING ADDRESS

9. FOR COMPLETION BY NONPROFIT ORGANIZATIONS AUTHORIZED TO MAIL AT SPECIAL RATES (Sctlon 411.3 0MM only) The purpose, function, and nonprofit status of this organization and the exempt status for Federal income tax purposes (Chck one)

(1) (2) i#{149};;iHAS NOT CHANGED DURING J HAS CHANGED DURING (II chsngid, publisher must submit xplanstlon of .,PRECEDING 12 MONTHS PRECEDING 12 MONTHS change with this stst.nsst.) AVERAGE NO. COPIES EACH ACTUAL NO. COPIES OF SINGLE 10. EXTENT AND NATURE OF CIRCULATION ISSUE DURING PRECEDING ISSUE PUBLISHED NEAREST TO 12 MONTHS FILING DATE

A, TOTAL NO. CONES (Net Pri*a Run) 2107 2100 B. PASO CIRCULATION 1. SALES THROUGH DEALERS AND CARRIERS. STREET VENDORS AND COUNTER SALES none none a MAIL SUSSCRIPT1ON 1521 1511

C. TOTAL PAID CIRCULATION (Sum of 1081 and 1M2) 1521 1511

D. FREE DISTRIBUTION BY MAIL, CARRIER OR OTHER MEANS SAMPLES. COMPLIMENTARY. AND OThER FREE COPIES 77 68

E. TOTAL DISTRIBUTION (Sum of C and 0) 1598 1579

F. COPIES NOT DISTRIBUTED 1. OFFICE USE, LEFT OVER, UNACCOUNTED. SPOILED AFTER PRINTING 509 521

2. RETURN FROM NEWS AGENTS none none

0. TOTAL (Sum of E, Fl and 2 - shoid iqu net pr.sa nm shown In A) 2107 2100

oRAwN cetive Officer 11. meI certIfyabove thatare thecorrectstatementsand completemade by SSGNAi , RE AN TITLE OF EDITOR. PUBLISHER, 8USINESS

PS Fore, (P595 1) July 1981 (See I,stncfIon on reverse) NOTICE

Molecular Pharmacology is no longer considering manuscripts for publication as “Short Communications.” Notice to Authors Wishing to Submit Manuscripts to

Journal ofPharmacology and Experimental Therapeutics

Molecular Pharmacology

Drug Metabolism and Disposition

The expenses associated with the review of manuscripts submitted to those ASPET- sponsored journals that are devoted to publishing original research articles have escalated dramatically in recent years because of ever-increasing costs of postage, supplies, and other office expenses, and the growing number of manuscripts submitted for publication. In order to continue to offer authors the opportunity to publish their original research in our critically reviewed, well-edited, and widely respected journals, it has become necessary for ASPET to follow the example of several other scientific societies which have instituted a uniform manuscript handling fee for each of its journals that publishes original research reports. Therefore, all manuscripts received in the editorial office on or after July 1, 1983, must be accompanied either by a check for $30.00 (in U. S. funds payable to ASPET) or by a validated purchase order from the authors’ institution. The review process for submitted manuscripts wifi be delayed until the manuscript handling fee or purchase order is received in the appropriate Editor’s office. We regret the necessity of instituting a manuscript handling fee. The Board of Publications Trustees has concluded, however, that this charge represents the fairest and most appropriate manner to defray the CoSts related to the review of submitted manuscripts. If submission of the manuscript handling fee entails a personal financial hardship to the author(s), the fee will be waived. In that event, the author(s) should submit a request for waiver of the fee when the manuscript is submitted. INSTRUCTIONS TO AUTHORS

Molecular Pharmacology will publish the results ofinvestigations that contribute significant new information on drug action or selective toxicity at the molecular level. The term “drug” is defined broadly to include chemicals that selectively modify biological function.

Suitable papers are those that describe applications of the methods of biochemistry, biophysics, genetics, and molecular biology to problems in pharmacology or toxicology. Also suitable are reports of fundamental investigations which, although not concerned directly with drugs, nevertheless provide an immediate basis for further study of the molecular mechanism of drug action. Observations of phenomena that shed no light upon underlying molecular interactions are not appropriate for publication. Comparative studies, such as those involving drug-receptor or drug-enzyme interactions that already have been well characterized in other types of cells or tissues, also are inappropriate for publication unless they contribute significant new insight into mechanisms.

Specific areas of interest include: stereochemical, electronic, and other parameters of drug architecture; conformational analysis of receptors and their function; drug-enzyme and other interactions between drugs and macromolecules; drug effects upon gene replication and transcription and on protein synthesis; mechanism of action of antibiotics and other growth-inhibitory drugs; induction by drugs of changes in macromolecular structure or allosteric transitions; drug-induced alterations in metabolic pathways; effects of hormones and other drugs on cellular regulatory mechanisms; chemical mutagenesis, carcinogenesis, and teratogenesis; pharmacogenetics, idiosyncrasies, and drug allergies; selective toxicity in a single organism or in different species; drug actions on properties and functions of membranes; mechanisms of drug metabolism; distribution and transport of drug molecules between biological compartments.

Page charges. Authors will be billed at the rate of $30.00 per Original figures and single copies of manuscripts not accepted for page after the paper has been published. It is expected that the page publication will be returned to the authors upon request. charge will be paid if funds are available for that purpose from the It is understood that the manuscripts and the results they contain author’s institution or from the sponsor of this research. Payment will not have been published previously and are not being submitted of the charge is not a condition for publication. In case of personal elsewhere. Manuscripts are accepted for review with the under- financial hardship, page charges will be waived. Neither the editors standing that all persons listed as authors have given their approval nor the reviewers will have knowledge as to who has paid the for the submission of the paper; further, that any person cited as a charge, and this payment always will be considered entirely volun- source of personal communications has approved such citation. tary. Written authorization may be required at the Editor’s discretion.

Submission ofmanuscript. Manuscripts are published in English Articles and any other material published in Molecular Pharma- only and should be sent to Dr. Joel Hardman, Editor, Molecular cology represent the opinions of the author(s) and should not be Pharmacology, Department of Pharmacology, Vanderbilt construed to reflect the opinions of the Editor(s) and the Publisher. University Medical Center, Nashville, Tennessee 37232, If and when a manuscript is published, it will become the sole U. S. A. property of the Journal. The expenses associated with the review of manuscripts submit- Authors submitting a manuscript do so on the understanding that ted to Molecular Pharmacology and other ASPET-sponsored jour- if it is accepted for publication, copyright in the article, including nals that are devoted to publishing original research articles have the right to reproduce the article in all forms and media, shall be escalated dramatically in recent years because of ever-increasing assigned exclusively to the Society for Pharmacology and Experi- costs of postage, supplies, and other office expenses, and the growing mental Therapeutics. No reasonable request by the author for number of manuscripts submitted for publication. Thus, it has permission to reproduce any of his or her contributions to the become necessary for ASPET to follow the example of several other journal will be refused. scientific societies which have instituted uniform manuscript han-

dling fees. Therefore, all manuscripts must be accompanied either Organization and style ofmanuscripts. The policy of the Journal check for by a $30 (in U. S. funds payable to ASPET) or by a is to allow authors maximum freedom in organizing and presenting validatedpurchase order from the authors’ institution. The review their material, and in expressing their ideas, provided only that process for submitted manuscripts will be delayed until the manu- clarity and conciseness are achieved. For most manuscripts, the script handling fee or purchase order is received in the Editor’s most suitable format is: (1) Summary, (2) Introduction, (3) Materials office. If submission of the manuscript handling fee entails a per- and Methods, (4) Results, and (5) Discussion. sonal financial hardship to the author(s), the fee will be waived. In that event, the author(s) should submit a request for waiver of the Certain conventions must be observed. Chemical and mathemat- fee when the manuscript is submitted. ical formulas and abbreviations should follow the Instructions to Manuscripts should be typewritten double-spaced with ample Authors ofthe Journal ofBiological Chemistry (Vol. 258, pp. 1-11, margins on one side of the paper, 8#{189}x 11 inches (ca. 215 x 280 January 10, 1983). Drugs must be referred to by their generic or mm). Submit four complete copies ofthe manuscript and four copies chemical names throughout the text, but may be identified by trade of each figure, plus one original drawing or photograph of each name in parentheses or a footnote. The systematic name and figure. Each half-tone figure requires four original drawings or number given by the Commission on Enzymes of the International photographs. All pages should be numbered consecutively beginning Union of Biochemistry should be included for each enzyme of with the title page. Limit your reference listings to the minimal importance in a paper, at the point in the Summary or Introduction number required to document the manuscript adequately. In most where the enzyme is first mentioned. The use of abbreviations instances 30 references or fewer should suffice. should be minimized and abbreviations avoided in the Summary. Under usual circumstances reviewers will be instructed to return All essential abbreviations should be defined in a single footnote only their comments to the editorial office and to destroy manu- when first introduced. Abbreviations of journal names should con- scripts after a final decision on their acceptability has been made. form to the style of Biological Abstracts. References to papers that have been accepted for publication, but have not appeared, should section, or under another table or figure). Footnotes to tables should be cited like other references with the abbreviated name of the appear beneath the tables themselves and should be designated by journal followed by the words “in press.” Copies of such papers lower-case italic superscript letters, a, b, c, etc. should be sent whenever the findings described in them have a direct bearing on the paper being submitted for publication. “Per- Figures. These should be numbered with arabic numerals. Each sonal Communications” and “Unpublished Observations” should be of the four manuscript copies should contain all of the figures. Only cited in footnotes to the text and should not be included in the the orignal set need be of quality suitable for reproduction except in reference list. the case of half-tones, which require four sets of photographs or original drawings. These should be unmounted glossy photographs (or original India-ink drawings). Usually figures will be reduced to A manuscript should include the following, in the order listed: (1) one column width (85 mm) and all numbers after such reduction Title. Numbered footnotes to the title should be avoided; acknowl- should be at least 1.5 mm high. The figures must be ready, in all edgment of financial support should be given in an unnumbered respects, for direct reproduction: no lettering or other art work will footnote to the title. (2) Names of authors, their laboratory and be done by the publisher. If symbols are not explained on the face institution. (3) A running title, not exceeding 60 characters and of the figure, only standard characters, of which the printer has spaces. (4) Summary. (5) Text. Footnotes should be referred to by type, may be used (x, 0, #{149},0, #{149},L, A, C). The back of each superscript numbers and references by numbers in parentheses. (6) photograph should bear its number, and the legend TOP at the References, numbered according to order of citation in the text, appropriate edge. The list of legends for the figures should give including title and complete pagination. Examples: 1. Goren, J. H., captions and sufficient experimental detail, as required for tables. L. G. Bauce, and W. Vale. Forces and structural limitations of binding of thyrotropin-releasing receptor: the pyroglutamic acid Galley proof The cost of all changes on galley proof, other than moiety. Mol. Pharmacol. 13:606-614 (1977). 2. Sandier, M. Varia- printer’s errors, will be charged to authors. The Editors are very tions in monoamine oxidase activity in some human disease states, much interested in having accepted contributions appear in the in Monoamine Oxidase and Its Inhibition. Ciba Foundation Sym- earliest possible issue of the Journal, and therefore request that posium 39. Elsevier, Amsterdam, 327-340 (1976). (7). Footnotes, galley proof be returned within 24 hours after its receipt. In excep- numbered according to order of appearance in the text. (8) Tables. tional cases, a “Note added in proof” may be attached and will be (9) Figures. (10) Legends to figures. (11) Name and address of published if the Editor approves. person to receive galley proof. Reprints andpage charges. An order form for reprints as well as Tables. These should be numbered with arabic numerals and information on the estimation of page charges will be mailed with designed to fit the single-column width ofthe full-page width. Every galley proof. Please direct questions on reprints, page charges, or table should have an explanatory title and sufficient experimental other business matters to Kay Croker, Executive Officer, American detail in a paragraph following the title to be inteffigible without Society for Pharmacology and Experimental Therapeutics, 9650 references to the text (unless the procedure is given in the Methods Rockville Pike, Bethesda, Md. 20814. Telephone (301)530-7060.